BMI

Trends in cardiovascular disease biomarkers and their socioeconomic patterning among adults in the Scottish population 1995 to 2009: cross-sectional surveys

Joel William Hotchkiss,¹ Carolyn Anne Davies,¹ Linsay Gray,¹ Catherine Bromley,² Simon Capewell,³ Alastair Leyland¹

ABSTRACT

Objectives: To examine secular and socioeconomic changes in biological cardiovascular disease risk factor and biomarker prevalences in the Scottish population. This could contribute to an understanding of why the decline in coronary heart disease mortality in Scotland has recently stalled along with persistence of associated socioeconomic inequalities.

Design: Cross-sectional surveys.

Setting: Scotland.

Participants: Scottish Health Surveys: 1995, 1998, 2003, 2008 and 2009 (6190, 6656, 5497, 4202 and 4964 respondents, respectively, aged 25–64 years). **Primary outcome measures:** Gender-stratified, age-standardised prevalences of obesity, hypertension, hypercholesterolaemia and low high-density lipoprotein cholesterol blood concentration as well as elevated fibrinogen and C reactive protein concentrations according to education and social class groupings. Inequalities were assessed using the slope index of inequality, and time trends were assessed using linear regression.

Results: The prevalence of obesity, including central obesity, increased between 1995 and 2009 among men and women, irrespective of socioeconomic position. In 2009, the prevalence of obesity (defined by body mass index) was 29.8% (95% CI 27.9% to 31.7%) for men and 28.2% (26.3% to 30.2%) for women. The proportion of individuals with hypertension remained relatively unchanged between 1995 and 2008/2009, while the prevalence of hypercholesterolaemia declined in men from 79.6% (78.1% to 81.1%) to 63.8% (59.9% to 67.8%) and in women from 74.1% (72.6% to 75.7%) to 66.3% (62.6% to 70.0%). Socioeconomic inequalities persisted over time among men and women for most of the biomarkers and were particularly striking for the anthropometric measures when stratified by education.

Conclusions: If there are to be further declines in coronary heart disease mortality and reduction in associated inequalities, then there needs to be a favourable step change in the prevalence of

ARTICLE SUMMARY

Article focus

- In Scotland, as in other developed countries, coronary heart disease mortality has substantially declined over time.
- This decline may have slowed among younger ages and there are still large socioeconomic inequalities in mortality.
- Examination of the secular and socioeconomic changes in biological cardiovascular disease risk factor and biomarker prevalences in the Scottish population.

Key messages

- In Scotland, over a 14-year period since 1995, there has been a substantial increase in the prevalence of obesity with a persistence of large inequalities.
- At the same time, the prevalence of hypertension has changed little, while that of hypercholesterolaemia has declined, albeit from a very high level. Inequalities were generally smaller and, in the case of cholesterol in men, ill defined.
- Such trends can only serve to curb any further declines in coronary heart disease mortality and maintain associated inequalities.

Strengths and limitations of this study

- This study utilised data from nationally representative surveys conducted over a 14-year period.
- Bias may have been introduced by declining survey response levels. Differential non-response by the socioeconomically disadvantaged may lead to an underestimation of the magnitude of inequalities.

cardiovascular disease risk factors. This may require radical population-wide interventions.

To cite: Hotchkiss JW, Davies CA, Gray L, *et al.* Trends in cardiovascular disease biomarkers and their socioeconomic patterning among adults in the Scottish population 1995 to 2009: cross-sectional surveys. *BMJ Open* 2012;**2**:e000771. doi:10.1136/ bmjopen-2011-000771

Prepublication history and additional materials for this paper are available online. To view these files please visit the journal online (http://dx. doi.org/10.1136/ bmjopen-2011-000771).

Received 15 December 2011 Accepted 5 April 2012

This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence; see http://bmjopen.bmj.com

¹Measuring Health, MRC/CSO Social and Public Health Sciences Unit, Glasgow, UK ²Scottish Centre for Social Research, Edinburgh, UK ³Division of Public Health, University of Liverpool, Liverpool, UK

Correspondence to

Dr Joel William Hotchkiss; joel.hotchkiss@sphsu.mrc. ac.uk

INTRODUCTION

The rapid absolute decline in Scottish coronary heart disease (CHD) mortality since the 1970s¹ has slowed from 1994 onwards for individuals <55 years of age.² Such plateaus in CHD mortality rates have also been identified in the USA, Australia and England.^{3–5} Risk factor reduction is believed to account for at least half of the decline that has occurred, the remainder being mainly ascribed to advancements in treatment.^{6–8}

There is a persistent socioeconomic gradient across CHD mortality in many countries, and in some places, inequalities may be widening.² ⁹ Much of the excess CHD associated with socioeconomic disadvantage can be explained by the corresponding patterning in cardio-vascular disease (CVD) risk factors.^{10–12}

In Scotland, over a 13-year period leading up to 2008, there had been minimal decline in behavioural CVD risk factors and no substantial change in socioeconomic inequalities.¹³ Of further concern is the increase in self-reported diabetes and hypertension during this time. This study investigates the socioeconomic patterning of biological CVD risk factors and markers that are intermediate between behavioural risk factors and CHD, in Scotland between 1995 and 2009. Our hypothesis was that there would be stagnation in prevalence trends in these biomarkers for CVD and that this might provide some explanation for the worrying trends in CHD mortality.

METHODS

Survey method and sample

The 1995, 1998, 2003, 2008 and 2009 Scottish Health Surveys (SHeSs) are cross-sectional nationally representative surveys reporting the health and health-related behaviours (with emphasis on CVD) of people living in private households in Scotland; details are described elsewhere.^{14–18} Briefly, samples were selected using a multistage, stratified, clustered probability sampling design. Data were collected during two household visits: first by an interviewer and then by a nurse. During the face-to-face interviews, information such as age, gender, educational status and occupational social class was ascertained. Bodyweight was measured to the nearest 100 g using electronic scales, an estimate was requested from respondents that exceeded the scales' upper limit of 130 kg. Height was measured to the nearest millimetre using a stadiometer.

During the nurse visit, blood pressure measurements, details of prescription drug use and non-fasting venous blood samples, as well as waist and hip circumferences, were obtained. The latter were measured using a tape with an insertion buckle and recorded to the nearest millimetre with at least two measurements combined to provide a mean. The waist was defined as the midpoint between the lower rib and the upper margin of the iliac crest. Hips were measured at the widest circumference around the buttocks below the iliac crest.

Blood pressure readings were taken using an automated device with the informant in a seated position, after a 5 min rest. Data used in this study are based on the mean of the second and third readings of participants that had not eaten, smoked, drunk alcohol or taken vigorous exercise in the 30 min preceding measurement. The first two surveys employed Dinamap 8100 monitors (Critikon, Tampa, Florida, USA), while from 2003, Omron HEM 907 devices (Omron Healthcare, Kyoto, Japan) were used. Regression equations generated from a calibration study were used to derive predicted Omron readings from Dinamap readings.¹⁵

The same laboratory conducted blood sample analyses except for the 1995 survey. Total cholesterol serum concentration was determined by a cholesterol oxidase assay. In 1995 and 1998, high-density lipoprotein (HDL) cholesterol serum concentration was estimated using the cholesterol oxidase assay following PTA precipitation. From 2003, a direct method was used for analysis. Serum C reactive protein was estimated from 1998 onwards using the N Latex CRP mono Immunoassay. Plasma fibrinogen concentration was estimated using a modification of the Clauss thrombin clotting method, again from 1998 with different analysing equipment used from 2008.

The 2008 and 2009 surveys were part of a continuous survey running until 2011; sample sizes were smaller than in previous surveys and the nurse interview was a subsample (tables 1 and 2). The main interview response proportion declined from 81% in 1995 to 56% in 2009. The surveys were age limited in 1995 (16-64 years) and in 1998 (2-74 years). Analyses were restricted to individuals aged between 25 and 64 years at the time of interview for all surveys. The lower limit was adopted because educational achievement is believed to be relatively stable by this age, while the 1995 survey dictated the upper limit. To ensure nationally representative data, the nurse examination subsamples from 2008 (n=720) and 2009 (n=762) were merged. Pregnant women were excluded from all measurements and the blood sample collection.

Risk factors and risk markers

Biomarkers were dichotomised, using thresholds that indicated increased risk of CVD, as follows: body mass index (BMI; weight (kg) divided by height squared (m²)) with obesity defined as $\geq 30 \text{ kg/m}^{2-19}$; genderspecific definitions of excessive waist circumference (WC) were ≥ 102 cm for men, ≥ 88 cm for women¹⁹; waist-hip ratio (WHR; WC divided by hip circumference) excess was defined as ≥ 1 and ≥ 0.85 for men and women, respectively¹⁹; hypertension (uncontrolled) was reported for those individuals with systolic pressure \geq 140 mm Hg or diastolic pressure \geq 90 mm Hg, irrespective of treatment²⁰; hypercholesterolaemia was defined as a serum total cholesterol $\geq 5.0 \text{ mmol/l}$, medication was ignored²¹; high-risk HDL cholesterol serum concentration was defined by gender-specific thresholds: <1.0 mmol/l for men and <1.2 mmol/l for women²¹; total cholesterol: HDL cholesterol ratio cut-off
 Table 1
 Characteristics of the 1995, 1998, 2003, 2008 and 2009 Scottish Health Surveys: interview samples restricted to 25–64-year old respondents (unweighted data)

	Scottish Hea	Ith Survey			
	1995	1998	2003	2008	2009
Sample size, n	6910	6656	5497	4202	4964
Mean age (SD)	43.3 (11.6)	43.8 (11.3)	45.3 (10.9)	46.0 (11.0)	45.6 (11.0)
Gender, n (%)					
Male	3049 (44.1)	2969 (44.6)	2437 (44.3)	1839 (43.8)	2136 (43.0)
Female	3861 (55.9)	3687 (55.4)	3060 (55.7)	2363 (56.2)	2828 (57.0)
Ethnicity, n (%)					
White	6852 (99.2)	6571 (98.7)	5357 (97.5)	4066 (96.8)	4819 (97.1)
Other	55 (0.8)	70 (1.1)	103 (1.9)	117 (2.8)	112 (2.3)
Missing	3 (0.0)	15 (0.2)	37 (0.7)	19 (0.5)	33 (0.7)
BMI, n (%)					
<30 kg/m ²	5158 (74.6)	4691 (70.5)	3447 (62.7)	2519 (59.9)	2949 (59.4)
\geq 30 kg/m ² , obese	1218 (17.6)	1359 (20.4)	1207 (22.0)	1090 (25.9)	1270 (25.6)
Missing*	534 (7.7)	606 (9.1)	843 (15.3)	593 (14.1)	745 (15.0)
Social class, n (%)					
I, professional	297 (4.3)	280 (4.2)	316 (5.7)	225 (5.4)	277 (5.6)
II, managerial	1644 (23.8)	1696 (25.5)	1646 (29.9)	1232 (29.3)	1670 (33.6)
IIINM, skilled non-manual	1534 (22.2)	1404 (21.1)	1125 (20.5)	889 (21.2)	1011 (20.4)
IIIM, skilled manual	1424 (20.6)	1348 (20.3)	984 (17.9)	773 (18.4)	839 (16.9)
IV, semi-skilled manual	1111 (16.1)	1177 (17.7)	939 (17.1)	703 (16.7)	794 (16.0)
V, unskilled manual	575 (8.3)	468 (7.0)	320 (5.8)	253 (6.0)	252 (5.1)
Other (armed forces, unknown)	325 (4.7)	283 (4.3)	167 (3.0)	127 (3.0)	121 (2.4)
Education, n (%)					
Level, 3 degree level or above	1793 (25.9)	1727 (25.9)	1482 (27.0)	1177 (28.0)	1458 (29.4)
Level, 2 intermediate	1043 (15.1)	1209 (18.2)	1070 (19.5)	1046 (24.9)	1265 (25.5)
Level 1, end of compulsory schooling	1839 (26.6)	1723 (25.9)	1641 (29.9)	1156 (27.5)	1337 (26.9)
No qualifications	2226 (32.2)	1978 (29.7)	1274 (23.2)	802 (19.1)	888 (17.9)
Other qualifications or missing	9 (0.1)	19 (0.3)	30 (0.5)	21 (0.5)	16 (0.3)
Nurse sample size selected, n	6910	6656	5497	1193	1255
Declined nurse	306 (4.4)	387 (5.8)	867 (15.8)	278 (23.3)	275 (21.9)
Agreed to nurse visit but not completed	525 (7.6)	752 (11.3)	913 (16.6)	195 (16.3)	218 (17.4)
Agreed to nurse visit and completed	6079 (88.0)	5517 (82.9)	3717 (67.6)	720 (60.4)	762 (60.7)
*Missing for body mass index (BMI) included preg	nant women.				

for increased risk was 4.5, irrespective of medication; for both fibrinogen and C reactive protein values in the highest quintile determined for each survey sample as a whole, stratified by gender, were defined increased risk. Total cholesterol and hypertension were investigated irrespective of drug treatment as this study was interested in risk marker changes, whatever the cause.

Socioeconomic measures

Individual respondents' Registrar General's occupational social class was divided into seven categories I, II, III non-manual, III manual, IV, V and others (including armed forces/unknown). From 2003, the Registrar General's social class was not directly recorded, this necessitated its derivation from the National Statistics Socio-Economic Classification (NS-SEC).²² ²³ The highest educational qualification that respondents achieved was divided into four levels: no qualifications, level 1: age at end of compulsory schooling =16 years from 1971, 15 years from 1947 and 14 years prior to 1947 (O grade, standard grade, GCSE or equivalent), level 2 (higher grade, A level, GSVQ advanced or equivalent and HNC, HND, SVQ level 4 or 5 or equivalent) and level 3 (first degree, higher degree or professional qualifications). Between each survey, there was slight variation in the questions used to determine educational attainment to reflect changes in the education system.

Statistical analyses

The prevalence of each risk factor was determined for the period 1995–2008/2009 according to social class or education; participants in the 'other' categories were excluded (tables 1 and 2). Individuals with missing data were excluded from affected analyses. Survey weights were used to adjust for disproportionate sampling, differing selection probabilities and differential nonresponse. Nurse sample and blood sample weights were available for the 2003 and 2008/2009 data sets. Genderstratified prevalences were age standardised (direct method) to the European standard population using 5year age groups.²⁴ For each risk factor and survey year, the slope index of inequality (SII), an absolute measure of inequality, was estimated using the weighted least squares method. The SII is the linear regression
 Table 2
 Characteristics of the 1995, 1998, 2003, 2008 and 2009 Scottish Health Surveys: nurse samples restricted to 25–64-year old respondents (unweighted data)

	Scottish Heal	th Survey			
	1995	1998	2003	2008	2009
Nurse sample size, n	6079	5517	3717	720	762
Mean age (SD)	43.4 (11.5)	44.1 (11.2)	45.9 (10.8)	46.5 (10.9)	46.3 (11.1)
Gender, n (%)					
Male	2703 (44.5)	2479 (44.9)	1614 (43.4)	325 (45.1)	315 (41.3)
Female	3376 (55.5)	3038 (55.1)	2103 (51.5)	395 (54.9)	447 (58.7)
Waist circumference, n (%)					
M <102; W <88 cm	4697 (77.3)	4035 (73.1)	2337 (62.9)	410 (56.9)	428 (56.2)
M ≥102; W ≥88 cm	1215 (20.0)	1374 (24.9)	1237 (33.3)	296 (41.1)	319 (41.9)
Missing	167 (2.7)	108 (2.0)	143 (3.8)	14 (1.9)	15 (2.0)
Waist-hip ratio, n (%)					
M <1.0; W <0.85	5052 (83.1)	4569 (82.8)	2697 (72.6)	507 (70.4)	523 (68.6)
M ≥1.0; W ≥0.85	831 (13.7)	835 (15.1)	868 (23.4)	199 (27.6)	224 (29.4)
Missing	196 (3.2)	113 (2.0)	152 (4.1)	14 (1.9)	15 (2.0)
Hypertension* (uncontrolled), n (%)					
SBP <140, DBP<90 mm Hg	4145 (68.2)	3646 (66.1)	2326 (62.6)	484 (67.2)	507 (66.5)
SBP \geq 140, DBP \geq 90 mm Hg	845 (13.9)	744 (13.5)	681 (18.3)	130 (18.1)	144 (18.9)
Missing	1089 (17.9)	1127 (20.4)	710 (19.1)	106 (14.7)	111 (14.6)
Blood sample, n (%)					
Yes	5498 (90.4)	4660 (84.5)	2984 (80.3)	607 (84.3)	618 (81.1)
No-refused	315 (5.2)	394 (7.1)	379 (10.2)	53 (7.4)	71 (9.3)
Missing†	266 (1.7)	463 (8.4)	355 (9.5)	60 (8.3)	73 (9.6)
Total cholesterol, n (%)‡					
<5.0 mmol	1267 (20.8)	1458 (26.4)	755 (20.3)	182 (25.3)	175 (23.0)
≥5.0 mmol/l	4184 (68.8)	3124 (56.6)	2115 (56.9)	400 (55.6)	404 (53.0)
Missing	628 (10.3)	935 (16.9)	847 (22.8)	138 (19.2)	183 (24.0)
HDL cholesterol, n (%)§					
M ≥1.0; W ≥1.2 mmol/l	4574 (75.2)	3755 (68.1)	2515 (67.7)	484 (67.2)	486 (63.8)
M <1.0; W <1.2 mmol/l	789 (13.0)	716 (13.0)	200 (5.4)	41 (5.7)	37 (4.9)
Missing	716 (11.8)	1046 (19.0)	1002 (27.0)	195 (27.1)	239 (31.4)
Total cholesterol: HDL cholesterol ratio					
<4.5	3272 (53.8)	2957 (53.6)	1910 (51.4)	389 (54.0)	385 (50.5)
≥4.5	2091 (34.4)	1513 (27.4)	804 (21.6)	136 (18.9)	138 (18.1)
Missing	716 (11.8)	1047 (19.0)	1003 (27.0)	195 (27.1)	239 (31.4)
Fibrinogen, n (%)¶					
Four quintiles	-	3399 (61.6)	2028 (54.6)	388 (53.9)	405 (53.1)
Highest quintile	-	800 (14.5)	473 (12.7)	102 (14.2)	82 (10.8)
Missing		1318 (23.9)	1216 (32.7)	230 (31.9)	275 (36.1)
C reactive protein, n (%)**					
Four quintiles	-	3573 (64.8)	2288 (61.6)	462 (64.2)	475 (62.3)
Highest quintile	-	937 (17.0)	570 (15.3)	120 (16.7)	104 (13.6)
Missing		1007 (18.3)	859 (23.1)	138 (19.2)	183 (24.0)
Social class, n (%)					
I, professional	265 (4.4)	228 (4.1)	221 (5.9)	38 (5.3)	46 (6.0)
II, managerial	1481 (24.4)	1427 (25.9)	1138 (30.6)	238 (33.1)	291 (38.2)
IIINM, skilled non-manual	1356 (22.3)	1187 (21.5)	776 (20.9)	149 (20.7)	155 (20.3)
IIIM, skilled manual	1261 (20.7)	1120 (20.3)	643 (17.3)	132 (18.3)	112 (14.7)
IV, semi-skilled manual	965 (15.9)	971 (17.6)	640 (17.2)	111 (15.4)	110 (14.4)
V, unskilled manual	488 (8.0)	381 (6.9)	207 (5.6)	36 (5.0)	37 (4.9)
Other (armed forces, unknown)	263 (4.3)	203 (3.7)	92 (2.5)	16 (2.2)	11 (1.4)
					Continued

Table 2 Continued					
	Scottish Healt	th Survey			
	1995	1998	2003	2008	2009
Education, n (%)					
Level 3, degree level or above	1610 (26.5)	1441 (26.1)	1072 (28.8)	223 (31.0)	248 (32.5)
Level 2, intermediate	925 (15.2)	1023 (18.5)	750 (20.2)	183 (25.4)	203 (26.6)
Level 1, end of	1644 (27.0)	1432 (26.0)	1084 (29.2)	185 (25.7)	185 (24.3)
compulsory schooling					
No qualifications	1894 (31.2)	1614 (29.3)	808 (21.7)	129 (17.9)	125 (16.4)
Other qualifications or missing	6 (0.1)	7 (0.1)	3 (0.1)	-	1 (0.1)

*1995 and 1998 blood pressure readings were taken using Dinamap monitors and then converted to Omron monitor readings. †Reasons for a missing blood sample included failed collection, pregnancy or a clotting disorder.

In 1995, a different laboratory completed analyses. Different analyses were used but methods and reference standards were the same. §Determined in 1995 and 1998 using a different method, not comparable to 2003 and 2008/2009. Thresholds for highest quintile of plasma fibrinogen concentration 1998: M >3.1 g/l, W >3.3 g/l; 2003: M >3.3 g/l, W >3.6 g/l; 2008/2009: M >3.4 g/l, W >3.6 g/l.

**Thresholds for highest quintile of serum C reactive protein concentration 1998: M >3.4 mg/l, W >4.3 mg/l; 2003: M>3.5 mg/l, W >4.8 mg/l; 2008/2009: M >3.71 mg/l, W >4.80 mg/l. Pregnant women were excluded from all measurements and the blood sample. DBP, diastolic blood pressure; HDL, high-density lipoprotein; M, manual; M, men; NM, non-manual; SBP, systolic blood pressure; W, women.

coefficient for the relationship between the prevalence of each risk factor in each socioeconomic category and the hierarchical ranking of each socioeconomic group category on the social scale.²⁵ It can be interpreted as the absolute change in health level when an individual goes from the highest status to the lowest status in the social hierarchy. In this context, a positive SII indicates that there is higher prevalence of an adverse CVD risk factor in the most disadvantaged compared with the least disadvantaged in the socioeconomic hierarchy. A positive SII is therefore bad from a public health perspective. Time trends for prevalence and the SIIs were assessed using generalised linear regression. For the aggregated 2008/2009 data sets, the year was taken as 2008.5. All analyses were performed using SAS V.9.2 (SAS Institute Inc.), and statistical significance was taken as p < 0.05.

Sensitivity analyses

Individuals taking drugs affecting blood pressure or lipid-lowering drugs were, respectively, excluded from involving hypertension analyses and hypercholesterolaemia. Also a definition of hypertension that included respondents on drugs prescribed for high blood pressure, irrespective of measurements, was investigated (1998 onwards). Similarly, the effect of including individuals taking lipid-lowering drugs in the high-risk total cholesterol group was explored. The proportion of individuals taking either drugs prescribed for hypertension or lipid-lowering drugs was also investigated. Limited within-survey response analyses were undertaken by comparing individuals that did not complete the nurse interview or give a blood sample with those that did comply with these requests; details of analyses and results are provided in section 3 of the supplementary information.

RESULTS

The participants' mean age increased across the five surveys, from 43.3 years in 1995 to 45.6 years in 2009

(table 1). The proportion of women was greater than that of men in all the surveys (tables 1 and 2). Over time, the population distribution shifted according to both socioeconomic measures. In general, the proportion of individuals in the 'upper' strata (eg, managerial class or level 3 qualifications) increased compared with those in the 'lower' strata (eg, unskilled class or no qualifications). Those that did not complete a nurse interview or a blood sample collection were more likely to be younger and to be smokers in almost all the surveys (supplementary tables 11-20). In the majority of the surveys, those from a lower socioeconomic background were less likely to have participated in later stages of the survey, particularly for the blood sample.

Overall, for individuals with data on education, the prevalence of obesity according to BMI increased by 0.7% per year (p<0.001) for men and 0.6% per year (p<0.001) for women (table 3). The fastest rate of increase was among unqualified men (0.9% per year, p=0.02) reaching a prevalence of 34.6% (95% CI 28.1% to 41.1%) in 2009. An educational differential was maintained in all the surveys; in 2009, the SII was 12.4 (p=0.08). The findings were similar for women; in 2009, those with no qualifications had the highest obesity prevalence (34.9%, 27.5% to 42.3%) and the SII was 17.4 (p=0.004). There were social class inequalities in obesity among women, although there was an overall decline in the SII from 1995 (-0.4, p=0.11) (table 4), while they were relatively small for men.

As for BMI, there were significant, or borderline significant, increases in the prevalence of excess adiposity in terms of both WC and WHR (tables 3 and 4). The proportion of men with excessive WHR was much lower than the proportions with extreme BMI or WC. In 1995, the three anthropometric measures yielded similar proportions of women with excess adiposity; however, by 2008/2009, a greater proportion had extreme values according to WC and WHR than BMI. Large educational inequalities existed for men and women for both WC

	Men							Women						
	Proportion (%) (95% CI)) (95% CI)					Trend	Proportion (%) (95% CI)	%) (95% CI)				Ļ	Trend
	1995	1998	2003	2008	8	2009	(p value)	1995	1998	2003	2008	2009	d)	(p value)
Obesity, BMI*														
All	19.2	21.7	24.9	28.3		29.8	0.7	19.5	23.8	25.5	27.5	28.2	0	0.6
	(17.8 to 20.7)	(20.2 to 23.2)	2) (23.1 to 26.7)	26.7) (26.3	.3 to 30.3)	(27.9 to 31.7)	-	(18.1 to 20.9)	(22.2 to 25.3)	(23.8 to 27.3)	(25.5 to 29.5)		(26.3 to 30.2) (<	(<0.001)
Level 3	14.8	17.2			0	24.2	0.7	16.2	19.1	20.2	20.5	22.0	0	0.3
	(11.7 to 17.9)	(14.1 to 20.2)			.2 to 28.5)	(20.8 to 27.6)	\sim	(13.9 to 18.5)	(16.5 to 21.6)	(17.1 to 23.4)			(18.9 to 25.2) (0.	(0.03)
Level 2	17.4	23.4			0	31.1	0.8	14.7	19.3	25.2		27.8	0	0.9
	(14.2 to 20.6)	(20.1 to 26.7)	7) (23.7 to 32.9)	32.9) (22.9	.9 to 30.8)	(27.3 to 34.8)	\sim	(9.7 to 19.6)	(13.8 to 24.8)	(21.0 to 29.5)	(23.1 to 31.5)		(24.0 to 31.5) (0.	(0.006)
Level 1	20.6	22.2	24.5	31.7	2	31.1	0.8	19.8	25.5	28.3	35.4	32.1	Ö	0.9
	(18.0 to 23.1)	(19.4 to 25.0)	0) (21.3 to 27.8)	27.8) (27.7	.7 to 35.7)	(27.3 to 34.9)	(0.005) (0	(16.7 to 23.0)	(22.0 to 28.9)	(24.9 to 31.6)	(31.4 to 39.4)		(28.2 to 36.1) (0.	(0.01)
No	23.2	25.3	26.6	36.9	6	34.6	0.9	22.7	27.8	30.9	26.6	34.9	0	0.5
qualifications	(20.1 to 26.2)	(21.8 to 28.7)	7) (22.1 to 31.0)	31.0) (29.9	.9 to 44.0)	(28.1 to 41.1)	1) (0.02)	(20.2 to 25.3)	(24.7 to 30.8)	(26.1 to 35.8)	(19.7 to 33.5)		(27.5 to 42.3) (0.	(0.18)
	10.6 (0.003)	8.3 (0.18)	6.8 (0.37)		0.03)	12.4 (0.08)	0.3 (0.33)	10.4 (0.06)	13.5 (0.04)	14.2 (0.01)	13.9 (0.32)	() 17.4 (0.004)		0.3 (0.08)
(p value)														
	Men							Women						
	Proporti	Proportion (%) (95% CI)	CI)				Trend	Proportion (%) (95% CI)	() (95% CI)				Trend	
	1995	1998	8	2003	200	2008/2009§	(p value)	1995	1998	2003	2008	2008/2009§	(p value)	
Excessive WC†														
AII	17.7	21.2	0.1	29.5	32.5	10	1.1	22.3	28.1	36.4	44.3		1.6 (0.002)	(7
	(16.3 to 19.1)		(19.7 to 22.7)	(27.4 to 31.6)	-	(29.2 to 35.8)	(0.02)	(20.8 to 23.9)	(26.4 to 29.8)	(34.1 to 38.6)		(40.8 to 47.8)		
Level 3	11.7	18.0		24.6	26.9		1.1	18.4	20.3	30.6	39.3		1.6 (0.008)	3)
	(8.7 to 14.7)	-	(14.8 to 21.2)	(20.9 to 28.3)	-	(21.2 to 32.5)	(0.04)	(15.9 to 20.9)	(17.6 to 23.1)			(33.0 to 45.6)		
Level 2	14.6		~	30.1		-	1.5	17.2	28.8				2.0 (0.03)	
	(11.5 to 17.8)	_	(17.7 to 24.3)	(24.7 to 35.4)	-	(27.8 to 40.9)	(0.02)	(11.0 to 23.5)	(22.6 to 34.9)			(39.9 to 53.2)		
Level 1	18.7			29.5			1.4	21.3	30.7				1.6 (0.04)	
		_	(17.9 to 23.5)	(25.6 to 33.3)	-	to 42.4)	(0.007)	(17.9 to 24.6)	(26.9 to 34.5)	_	_	(36.8 to 50.5)		
No qualifications			(0)	35.0	`	~	1.4	27.9	33.0				1.9 (0.02)	
	(19.6 to 25.7)	_	(22.0 to 29.2)	(29.5 to 40.6)	Ū	(30.2 to 49.7)	(0.01)	(25.0 to 30.8)	(29.6 to 36.3)			(43.5 to 61.6)		
SII (p value)	14.0 (<0.001	_	8.3 (0.11)	12.0 (0.08)		16.6 (0.03)	0.3 (0.46)	14.4 (0.06)	18.0 (0.05)	21.6 (0.02)		14.1 (0.16)	0.0 (0.99)	

Cardiovascular biomarker patterns

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Men					Women				
5193820032008/2009S(p value)19551938200320032008/2009S 8.6 10.0 14.5 0.5 (0.5) 18.0 19.2 34.4 37.8 $0.3.3$ $(7.5 to 9.6)$ $(8.6 to 11.4)$ $(12.0 to 16.9)$ 0.5 (0.05) 18.0 19.2 34.4 37.8 $to 7.0$ 5.0 5.4 9.6 0.3 (0.13) 14.5 13.2 $20.3.6.6$ $(34.4 to 41.2)$ 5.0 5.4 9.6 0.3 0.13 14.5 13.2 28.1 30.3 $to 7.0$ $(3.1 to 6.9)$ $(3.4 to 7.4)$ $(5.1 to 14.0)$ 0.3 (0.13) 14.5 $24.1 to 32.0$ $24.4 to 36.2$ $to 7.0$ $(3.1 to 6.9)$ $(3.4 to 7.4)$ $(5.1 to 14.0)$ 0.9 0.9 24.2 17.7 26.5 28.1 30.3 $to 8.8$ $(5.1 to 9.6)$ 9.9 24.2 $12.0 to 11.3$ $(12.2 to 25.4)$ 12.6 17.7 26.5 36.0 $to 9.9$ 24.2 $12.0 to 11.3$ $(12.2 to 25.4)$ $12.0 to 21.5$ $(12.4 to 21.9)$ $(14.9 to 21.5)$ $(21.4 to 36.1)$ $to 9.2$ $(7.0 to 11.1)$ $(7.4 to 12.5)$ $(17.6 to 30.8)$ 12.2 43.8 56.4 $to 9.1$ 14.3 $(12.2 to 28.5)$ $(20.3 to 28.5)$ $(20.2 to 28.5)$ $(38.3 to 49.2)$ $(47.2 to 65.7)$ $to 9.2$ $(7.0 to 11.1)$ $(11.2 to 17.4)$ $(12.6 to 38.4)$ (12.0) $(20.4 to 28.5)$ $(22.5 to 28.5)$ $(38.3 to 49.2)$ t		Proportion (%	() (95% CI)			Trend	Proportion (%)) (95% CI)			Trend
$ \begin{array}{llllllllllllllllllllllllllllllllllll$		1995	1998	2003	2008/2009§	(p value)	1995	1998	2003	2008/2009§	(p value)
8.28.610.014.50.5 (0.05)18.019.234.437.8 $(7.2 \ to 9.3)$ $(7.5 \ to 9.6)$ $(8.6 \ to 11.4)$ $(12.0 \ to 16.9)$ $(16.6 \ to 19.4)$ $(17.7 \ to 20.6)$ $(32.2 \ to 36.6)$ $(34.4 \ to 41.2)$ 5.0 5.4 9.6 $0.3 \ (0.13)$ 14.5 13.2 28.1 30.3 5.0 5.4 9.6 $0.3 \ (0.13)$ 14.5 13.2 28.1 30.3 $(3.0 \ to 7.0)$ $(3.1 \ to 6.9)$ $(3.4 \ to 7.4)$ $(5.1 \ to 14.0)$ $0.3 \ (0.07)$ 9.6 17.7 28.1 30.3 $(4.2 \ to 8.8)$ $(5.1 \ to 9.6)$ $(6.0 \ to 12.6)$ $(12.2 \ to 25.4)$ $(12.2 \ to 21.3)$ $(12.2 \ to 23.1)$ $(21.2 \ to 23.1)$ $(21.2 \ to 23.1)$ $(21.2 \ to 23.1)$ $(21.6 \ to 31.4)$ 7.5 9.0 9.9 24.2 $1.2 \ (0.11)$ 18.6 18.2 36.6 37.1 $(7.2 \ to 11.1)$ $(7.4 \ to 12.5)$ $(17.6 \ to 30.8)$ $(12.4 \ to 21.9)$ $(14.9 \ to 21.5)$ $(24.4 \ to 38.2)$ 7.5 9.0 9.9 24.2 $1.2 \ (0.10)$ 23.1 25.5 43.8 56.4 11.9 12.3 14.3 $(12.2 \ to 28.5)$ $(38.3 \ to 49.2)$ $(47.2 \ to 65.7)$ $8.4 \ (0.06)$ $8.9 \ (0.01)$ $10.7 \ (0.03)$ $24.4 \ (0.007)$ $12.3 \ (0.14)$ $17.3 \ (0.02)$ $22.5 \ to 28.5)$ $(34.4 \ to 38.7)$ $(42 \ to 14.3)$ $(12.2 \ to 28.5)$ $(24.4 \ to 38.7)$ $(24.7 \ to 65.7)$ 36.6 37.1 <	Excessive waist-h	lip ratio‡									
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	All	8.2	8.6	10.0	14.5	0.5 (0.05)	18.0	19.2	34.4	37.8	1.6 (0.05)
5.0 5.0 5.4 9.6 $0.3 (0.13)$ 14.5 13.2 28.1 30.3 $(3.0 b 7.0)$ $(3.1 b 6.9)$ $(3.4 b 7.4)$ $(5.1 b 14.0)$ $(12.2 b 16.8)$ $(10.9 b 15.5)$ $(24.1 b 32.0)$ $(24.4 b 38.2)$ 6.5 7.4 9.3 18.8 $0.9 (0.07)$ 9.6 17.7 26.5 36.0 $(4.2 b 8.8)$ $(5.1 t 09.6)$ $(6.0 t 12.6)$ $(12.2 t 0 25.4)$ $(12.2 t 0 23.1)$ $(21.6 t 031.4)$ $(29.5 t 0 42.5)$ 7.5 9.0 9.9 24.2 $1.2 (0.11)$ 18.6 18.2 36.8 37.1 7.5 9.0 9.9 24.2 $1.2 (0.11)$ 18.6 18.2 36.8 37.1 7.5 9.0 9.9 24.2 $1.2 (0.11)$ 18.6 $14.9 t 21.5)$ $(32.7 t 41.0)$ $(30.5 t 43.7)$ 11.9 12.3 14.3 $(12.6 t 38.1)$ $(22.5 t 28.5)$ $(38.3 t 49.2)$ $(47.2 t 66.57)$ $8.4 (0.06)$ $8.9 (0.01)$ $10.7 (0.03)$ $24.4 (0.007)$ $1.2 (0.11)$ $13.9 (0.14)$ $17.3 (0.02)$ $22.0 (0.08)$ $28.3 (0.13)$		(7.2 to 9.3)	(7.5 to 9.6)	(8.6 to 11.4)	(12.0 to 16.9)		(16.6 to 19.4)	(17.7 to 20.6)	(32.2 to 36.6)	(34.4 to 41.2)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Level 3	5.0	5.0	5.4	9.6	0.3 (0.13)	14.5	13.2	28.1	30.3	1.4 (0.08)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		(3.0 to 7.0)	(3.1 to 6.9)	(3.4 to 7.4)	(5.1 to 14.0)		(12.2 to 16.8)	(10.9 to 15.5)	(24.1 to 32.0)	(24.4 to 36.2)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Level 2	6.5	7.4	9.3	18.8	0.9 (0.07)	9.6	17.7	26.5	36.0	1.9 (0.004)
7.5 9.0 9.9 24.2 1.2 (0.11) 18.6 18.2 36.8 37.1 (5.8 to 9.2) (7.0 to 11.1) (7.4 to 12.5) (17.6 to 30.8) (15.4 to 21.9) (14.9 to 21.5) (32.7 to 41.0) (30.5 to 43.7) 11.9 12.3 14.3 27.8 12.2 12.0 (0.10) 23.1 25.5 43.8 56.4 11.9 12.3 12.6 17.2 (0.10) 23.1 25.5 43.8 56.4 11.9 12.3 12.3 (0.10) 23.1 25.5 23.3 to 49.2) (47.2 to 65.7) 13.6 (5 to 14.3) (9.6 to 14.3) (11.2 to 17.4) (19.6 to 36.1) (20.3 to 25.8) (22.5 to 28.5) (38.3 to 49.2) (47.2 to 65.7) 8.4 (0.06) 8.9 (0.01) 10.7 (0.03) 24.4 (0.007) 12.2 (0.11) 13.9 (0.14) 17.3 (0.02) 22.0 (0.08) 28.3 (0.13)		(4.2 to 8.8)	(5.1 to 9.6)	(6.0 to 12.6)	(12.2 to 25.4)		(4.9 to 14.3)	(12.2 to 23.1)	(21.6 to 31.4)	(29.5 to 42.5)	
(5.8 to 9.2) (7.0 to 11.1) (7.4 to 12.5) (17.6 to 30.8) (15.4 to 21.9) (14.9 to 21.5) (32.7 to 41.0) (30.5 to 43.7) 11.9 12.3 12.3 12.6 12.6 12.6 43.8 56.4 11.9 17.4 to 17.4) (19.6 to 36.1) 12.2 0.3.1 25.5 43.8 56.4 11.9 17.4 to 17.4) (19.6 to 36.1) 12.2 0.3.1 25.5 43.8 56.4 11.9 8.9 (0.01) 10.7 (0.03) 24.4 (0.007) 12.2 (0.11) 13.9 (0.14) 17.3 (0.02) 22.0 (0.08) 28.3 (0.13)	Level 1	7.5	9.0	9.9	24.2	1.2 (0.11)	18.6	18.2	36.8	37.1	1.6 (0.10)
11.9 12.3 14.3 27.8 1.2 (0.10) 23.1 25.5 43.8 56.4 s (9.6 to 14.3) (9.8 to 14.7) (11.2 to 17.4) (19.6 to 36.1) (20.3 to 25.8) (22.5 to 28.5) (38.3 to 49.2) (47.2 to 65.7) 8.4 (0.06) 8.9 (0.01) 10.7 (0.03) 24.4 (0.007) 1.2 (0.11) 13.9 (0.14) 17.3 (0.02) 22.0 (0.08) 28.3 (0.13)		(5.8 to 9.2)	(7.0 to 11.1)	(7.4 to 12.5)	(17.6 to 30.8)		(15.4 to 21.9)	(14.9 to 21.5)	(32.7 to 41.0)	(30.5 to 43.7)	
(9.6 to 14.3) (9.8 to 14.7) (11.2 to 17.4) (19.6 to 36.1) (20.3 to 25.8) (22.5 to 28.5) (38.3 to 49.2) (47.2 to 65.7) 8.4 (0.06) 8.9 (0.01) 10.7 (0.03) 24.4 (0.007) 1.2 (0.11) 13.9 (0.14) 17.3 (0.02) 22.0 (0.08) 28.3 (0.13)	No	11.9	12.3	14.3	27.8	1.2 (0.10)	23.1	25.5	43.8	56.4	2.6 (0.01)
8.4 (0.06) 8.9 (0.01) 10.7 (0.03) 24.4 (0.007) 1.2 (0.11) 13.9 (0.14) 17.3 (0.02) 22.0 (0.08) 28.3 (0.13)	qualifications	(9.6 to 14.3)	(9.8 to 14.7)	(11.2 to 17.4)	(19.6 to 36.1)		(20.3 to 25.8)	(22.5 to 28.5)	(38.3 to 49.2)	(47.2 to 65.7)	
	SII (p value)	8.4 (0.06)	8.9 (0.01)	10.7 (0.03)	24.4 (0.007)	1.2 (0.11)	13.9 (0.14)	17.3 (0.02)	22.0 (0.08)	28.3 (0.13)	1.1 (<0.001)

and WHR. Over half of unqualified women had an excessive WC (52.6%, 43.5% to 61.6%) and WHR (56.4%, 47.2% to 65.7%) in 2008/2009. For women, there was a significant increase in the WHR SII across education of 1.1 per year (p<0.001). There were also social class inequalities in WC and WHR (table 4).

Overall prevalence of hypertension (uncontrolled) in both sexes did not change significantly over time, although the trend was upwards (table 5). Prevalences generally increased between 1998 and 2003, coinciding with the change from predicted to actual Omron readings. Socioeconomic inequalities in hypertension were relatively small with the exception of those for social class among men in 2008/2009 (SII=13.9, p=0.05) (table 5). The larger inequalities partly reflect an increase in prevalence of 1.1% per year (p=0.01) among unskilled men from 1995. Sensitivity analyses, excluding respondents taking drugs affecting blood pressure or including those taking drugs prescribed for hypertension, identified similar socioeconomic patterns (supplementary tables 3 and 4). The proportion of respondents taking drugs prescribed for hypertension increased across the surveys with inequalities widening among men, those from lower in the hierarchy having a greater increase in uptake (supplementary tables 9 and 10).

Hypercholesterolaemia declined across the surveys: from 1995 to 2008/2009, among those with educational information, the prevalence decreased from 79.6% (78.1% to 81.1%) to 63.8% (59.9% to 67.8%) for men and from 74.1% (72.6% to 75.7%) to 66.3% (62.6% to 70.0%) for women (table 6). For both education and social class, inequalities were minimal for men except by education in 2008/2009. According to education, in the first three surveys, positive SIIs existed for women but in 2008/2009, the SII was -16.9 (p=0.23), while for social class, SIIs were generally small and positive (table 7). Sensitivity analyses, excluding those on lipid-lowering drugs or including them in the high-risk hypercholesterolaemia group, had minimal impact on estimates until the 2008/2009 survey where prevalences estimates were elevated, particularly among men (supplementary tables 5 and 6). The prevalence of individuals taking lipid-lowering drugs increased across the surveys while inequalities in uptake existed, with educational inequalities widening (supplementary tables 9 and 10).

There was minimal change in the prevalence of low HDL cholesterol between comparable surveys: namely 1995–1998 (supplementary tables 1 and 2) and 2003 to 2008/2009 (tables 6 and 7). There were significant educational inequalities for women in all surveys, in 2008/2009 the SII=11.9 (p=0.01) (table 6). Absolute inequalities for men were generally smaller than in women and in the case of social class were not consistent. The proportion with high total cholesterol: HDL cholesterol ratio decreased between comparable surveys (supplementary tables 7 and 8). Strong inequalities existed for women, while for men they were minimal.

	Men						Women					
	Proportion (%) (95% CI)) (95% CI)				Trend	Proportion (%) (95% CI)) (95% CI)				Trend
	1995	1998	2003	2008	2009	(p value)	1995	1998	2003	2008	2009	(p value)
Obesity, BMI*												
AII	19.2	21.8	25.1				19.3	23.6				
	(17.8 to 20.7)	(20.3 to 23.3)	(23.3 to 26.9)			Č	(17.8 to 20.7)	(22.0 to 25.2)	\sim		\sim	9
I, professional	7.8	16.1	14.0	23.9			13.1	12.4	18.4			
	(4.0 to 11.6)	(11.0 to 21.1)	(9.2 to 18.8)	(17.2 to 30.7)	_	Ξ	o 21.9)	(5.8 to 19.1)	(5.6 to 31.2)			9
II, managerial	20.2	22.0	23.8					21.6				
	(17.3 to 23.1)	(19.0 to 25.0)	(20.6 to 27.1)			9	to 17.8)	(18.6 to 24.5)	(18.9 to 25.0)			9.4) (0.02)
III, skilled NM	19.5	23.4	28.2					22.3	26.4			
	(14.8 to 24.2)	(18.5 to 28.2)	(22.4 to 34.1)		_	9	to 18.9)	(19.6 to 25.0)	(23.1 to	29.7) (24.7 to 32.1)		9
III, skilled M	20.4	21.8	29.4					25.0				
	(18.0 to 22.8)	(19.3 to 24.3)	(26.1 to 32.8)		_	5) (0.03)	to 31.3)	(19.7 to 30.3)				9
IV, partiy	1/.6	6.12 2 - 2 - 2 - 2	24.4					25.7	C.12			
skilled	(13.8 to 21.3)	(17.8 to 25.2)	(19.7 to 29.2)		<u> </u>	-	(20.3 to 27.9)	(22.1 to 29.3)	(23.3 to	31.7) (24.2 to 34.2)		9
V, unskilled	25.7	20.9	19.8				25.7	28.5				
	(18.4 to 33.0)	(13.8 to 28.1)	(11.4 to 28.2)	-		_	(20.7 to 30.7)	(23.0 to 33.9)	-			-
SII (p value)	5.5	1.5	1.1	-2.9	0.9	-0.4	14.9	9.0	10.7	5.9 (0.04)	8.4	-0.4
	(0.40)	(10.0)	(cc.n)	(00.0)	(0.8.0)	(00.0)	(enn.n)	(20.0)	(cn.n)	(10:0)	(0.10)	(11.0)
	Men						Women					
	Proportion	Proportion (%) (95% CI)¶	L			Trend	Proportion	Proportion (%) (95% CI)¶				Trend
	1995	1998	2003		2008/2009§	(p value)	1995	1998	2	2003	2008/2009§	(p value)
Excessive WC†												
AII	17.6	21.4	29.5		32.2	1.1	22.1	27.9	31	36.5	44.6	1.7
	(16.2 to 19.1)	9.1) (19.8 to 22.9)		(27.4 to 31.6) ((28.9 to 35.5)	(0.03)	(20.5 to 23.7)	7) (26.1 to 29.6)	Ŭ	34.2 to 38.7)	(41.0 to 48.1)	(0.002)
I, professional	7.7	16.4	16.0	.,	31.6	1.6	16.5	17.3	č	34.5	47.2	2.5
	(3.7 to 11.7)		_	to 21.7) ((19.9 to 43.4)	(0.07)	(7.0 to 26.1)		Ŭ	(24.9 to 44.0)	(31.3 to 63.1)	(0.02)
II, managerial	17.1				29.6	0.9	19.8		.,	33.0	44.3	1.8
	(14.3 to 19.9)	_		to 29.9)	(23.8 to 35.5)	(0.05)	(16.7 to 22.9)	_	<u> </u>	29.1 to 36.9)	(38.7 to 49.8)	(0.002)
III, skilled NM	17.6			(((30.9	1.0	18.2			36.3	45.3	2.0
III stalled III	(12.5 to 22.7)	_	_	to 38.0)	(19.8 to 42.1)	(0.12) 1 5	(15.7 to 20.7)	_	<u> </u>	32.3 to 40.4)	(38.7 to 51.9)	(0.005)
III, SKIIIEG M	18./ (10.0 ±- 01		-		0.05 (1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	C. L	C.12			41.4 (00 F ±= F0 4)	45.2	1.4
IV nartiv skillad	(16.3 10 21.U) d 18 5	1.U) (17.3 to 22.4) 20.7		10 41.8)	(29.4 TO 41.7) 20.1	(U. 13) 0.8	(21.8 to 33.3) 26.6	3) (24.0 10 30.0) 31 F		(32.5 to 50.4) 30 1	(32.4 IO 37.9) AA 6	(20.0) 1 3
iv, painty anim				to 315)	21.5 to 36.6)	(0.01)	(22 5 to 30 6)		. –	33.9 to 44.4)	(35.5 to 53.7)	(900.0)
V, unskilled	24.9				27.8	0.4	28.2		~ \	44.1	31.6	0.3
SII (p value)	(17.4 to 32.4) 8.3 (0.11)	2.4) (10.6 to 24.5) -2.6 (0.55)		(13.8 to 33.3) (11.4 (0.34)	(16.8 to 38.8) 1.2 (0.81)	(0.45) -0.1 (0.89)	(22.9 to 33.4) 12.2 (0.05)	 (31.3 to 44.0) 15.2 (0.004) 	.	(34.5 to 53.7) 11.2 (0.008)	(19.5 to 43.7) -3.3 (0.52)	(0.79) -1.2 (0.14)
												Continued

Cardiovascular biomarker patterns

	Men					Women				
	Proportion (%) (95% CI)) (95% CI)¶			Trend	Proportion (%) (95% CI)¶	(95% CI)¶			Trend
	1995	1998	2003	2008/2009§	(p value)	1995	1998	2003	2008/2009§	(p value)
Excessive waist-hip ratio	o ratio‡									
AII	8.2	8.6	10.1	14.6	0.5 (0.05)	17.6	18.9	34.4	37.9	1.7 (0.05)
	(7.2 to 9.3)	(7.5 to 9.7)	(8.7 to 11.5)	(12.1 to 17.0)		(16.1 to 19.0)	(17.4 to 20.4)	(32.2 to 36.6)	(34.4 to 41.4)	
I, professional	4.9	4.7	4.4	10.0	0.4 (0.22)	12.8	6.0	33.4	29.9	1.8 (0.21)
	(1.5 to 8.3)	(1.9 to 7.6)	(1.2 to 7.6)	(2.6 to 17.3)		(4.0 to 21.5)	(0 to 13.0)	(23.5 to 43.2)	(17.5 to 42.2)	
II, managerial	5.9	5.9	7.7	9.9	0.3 (0.02)	15.0	14.6	30.1	36.1	1.8 (0.04)
	(4.1 to 7.7)	(4.2 to 7.7)	(5.4 to 10.0)	(6.2 to 13.6)		(12.2 to 17.8)	(12.0 to 17.2)	(26.3 to 34.0)	(30.8 to 41.4)	
III, skilled NM	5.2	11.8	10.0	12.2	0.4 (0.30)	15.3	15.8	32.6	39.0	2.0 (0.03)
	(2.2 to 8.2)	(7.7 to 15.8)	(5.7 to 14.4)	(4.8 to 19.5)		(12.9 to 17.7)	(13.4 to 18.2)	(28.6 to 36.5)	(32.7 to 45.2)	
III, skilled M	10.1	9.7	12.2	18.5	0.6 (0.07)	23.8	24.4	34.4	46.0	1.7 (0.02)
	(8.2 to 12.0)	(7.8 to 11.6)	(9.4 to 15.0)	(13.6 to 23.4)		(18.4 to 29.2)	(18.9 to 29.9)	(26.0 to 42.8)	(32.6 to 59.5)	
IV, partly skilled	8.2	9.6	13.2	15.3	0.5 (0.009)	20.9	23.6	38.5	36.6	1.3 (0.12)
	(5.4 to 11.1)	(6.8 to 12.4)	(9.2 to 17.3)	(8.9 to 21.7)		(17.2 to 24.6)	(19.9 to 27.3)	(33.3 to 43.7)	(27.9 to 45.3)	
V, unskilled	15.7	9.7	9.1	16.0	0.1 (0.87)	21.4	29.2	50.4	31.3	1.0 (0.53)
	(9.7 to 21.7)	(4.3 to 15.0)	(3.1 to 15.1)	(7.8 to 24.2)		(16.7 to 26.1)	(23.4 to 34.9)	(40.8 to 60.0)	(18.7 to 43.9)	
SII (p value)	7.7 (0.06)	5.5 (0.11)	8.7 (0.02)	10.5 (0.05)	0.5 (0.14)	10.0 (0.03)	17.7 (0.009)	15.9 (0.04)	4.0 (0.51)	-0.6 (0.48)
Thresholds for high risk: *body mass index (BMI) ≥30 kg/m ² , †waist circumference (WC) men ≥102 cm, women ≥88 cm and ‡waist-hip ratio men ≥1, women ≥0.85 95% Cl.	risk: *body mass	index (BMI) ≥30 k	g/m², †waist circu	mference (WC) m	en ≥102 cm, wo.	men ≥88 cm and	‡waist-hip ratio m	len ≥1, women ≥	:0.85 95% CI.	
sivierged data set. Negative lower limit has been set to zero	it has heen set to	Zero								
M, manual; NM, non-manual; SII, slope index of inequality.	n-manual; SII, slop	the index of inequal	lity.							

Proportion (%) 1995 † 1995 † 19.2 17.3 17.4 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 18.0 20.8 19.7 20.8 3.4 0.27) 19.3 19.7 19.7 19.3 19.4 19.1 19.1 19.1 19.1 19.1 19.1	2003 22.5 22.5 (20.4 to 24.7) (20.4 to 24.7) (22.6 22.6 (18.7 to 26.5) (18.7 to 26.5) (16.0 to 26.7) (16.0 to 26.7) (16.0 to 26.3) (18.6 to 26.8) (18.6 to 26.8) (18.0 to 32.0) (25.0 22.7 (0.35) (0.35) (22.4 to 26.3)	2008/2009 ‡ 21.9 (18.7 to 25.1) 19.1 (13.9 to 24.4) 26.8 (20.0 to 33.7) 21.3 (15.3 to 27.2) 23.9 (15.3 to 27.2) 23.9 (14.3 to 33.5) 4.9 (0.57)	Trend (p value) 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.5 0.5 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Proportion (%) (95% Cl)* 1995 + 1998 + 1995 + 1998 + 13.6 13.3 12.4 13.3 12.4 12.8 10.2 to 14.9) (11.9 to 14) 13.8 11.5 13.8 11.5 to 14 13.8 11.5 (10.2 to 14.6) (5.1 to 17) 14.5 11.8 (11.4 to 17.7) (8.8 to 14) 14.3 14.3 (12.2 to 16.4) (12.2 to 16) 29 20) (95% Cl)* 1998† 13.3 (11.9 to 14.6) 12.8 (11.9 to 14.6) 12.8 (10.5 to 17.9) 11.8 (5.1 to 17.9) 11.8 (8.8 to 14.7) 14.3 (12.2 to 16.4)	2003 18.5 (16.7 to 20.4) 18.3 (14.8 to 21.9) 13.0 (8.9 to 17.1) 20.6 (17.0 to 24.2) 21.4 (16.5 to 26.4)	2008/2009 16.9 17.5 17.5 (12.5 to 19.5) 17.6 (7.5 to 17.7) 18.1 (12.6 to 23.6) 18.9 18.9	Trend (p value) 0.3 0.5 0.4 0.0 0.4 0.4 0.4 0.5 0.5 0.5 0.1 0.1
1995+ 19.2 19.2 17.3 17.8 (17.7 17.8 (17.7 17.8 (14.1 (14.1 17.8 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (14.1 (18.0 (18.0 (18.0 (18.0 (16.5 (16.5 (17.7 (17.7 (17.7 (13.1 (13.1 (13.1 (13.1 (13.1 (13.1 (13.1 (13.1	to 24.7) to 26.5) to 26.7) to 26.8) to 26.8) to 32.0)	2008/2009‡ 21.9 19.1 19.1 (13.9 to 25.1) 19.1 (13.9 to 24.4) 26.8 (20.0 to 33.7) 21.3 (20.0 to 33.7) 21.3 (15.3 to 27.2) 23.9 23.9 (14.3 to 33.5) 4.9 (0.57)	(p value) 0.3 0.22 0.2 0.2 0.2 0.2 0.2 0.2 0.5 0.2 0.2 0.2 0.2 0.2 0.2 0.2	1995 † 13.6 (12.3 to 14.9) 12.4 (10.2 to 14.6) 13.8 (8.1 to 19.6) 14.5 (11.4 to 17.7) 14.3 (11.2 to 16.4) 14.3	1998 † 13.3 13.3 (11.9 to 14.6) 12.8 (10.5 to 15.1) 11.5 (5.1 to 17.9) 11.8 (8.8 to 14.7) 14.3 (2.1 2 to 16.4)	2003 18.5 (16.7 to 20.4) 18.3 (14.8 to 21.9) 13.0 (8.9 to 17.1) 20.6 (17.0 to 24.2) 21.4 (16.5 to 26.4)	2008/2009‡ 16.9 17.5 17.5 (12.5 to 19.5) 17.5 (12.6 to 22.5) 18.1 (7.5 to 17.7) 18.1 (12.6 to 23.6) 18.9	(p value) 0.3 (0.24) 0.5 (0.14) 0.4 (0.32) 0.4 (0.32) 0.5 (0.32) 0.5
19.2 17.7 17.8 17.8 14.1 to 21.5) 17.8 14.1 to 21.4) 14.1 to 21.4) 14.1 to 21.4) 14.1 to 21.4) 20.8 (14.1 to 21.4) (18.0 to 23.5) (18.0 to 23.5) (18.0 to 23.5) (18.0 to 23.5) (18.0 to 23.5) (18.0 to 23.5) (18.0 to 23.5) (18.1 to 20.9) (17.7 to 20.9) (13.1 to 25.1) (13.1 to 25.1) (13.1 to 25.1) (13.1 to 25.1)	 to 24.7) to 26.5) to 26.5) to 26.3) to 26.8) to 26.8) to 24.6) 	21.9 (18.7 to 25.1) 19.1 (13.9 to 24.4) 26.8 (20.0 to 33.7) 21.3 21.3 (15.3 to 27.2) 23.9 (14.3 to 33.5) 4.9 (0.57)	0.3 0.2 0.2 0.7 0.7 0.7 0.2 0.2 0.2 0.5 0.2 0.2 0.2 0.2 0.2 0.2	13.6 (12.3 to 14.9) 12.4 (10.2 to 14.6) 13.8 (8.1 to 19.6) 14.5 (11.4 to 17.7) 14.3 (11.4 to 17.7) 14.3 (12.2 to 16.4) 2.9	13.3 (11.9 to 14.6) 12.8 (10.5 to 15.1) 11.5 (5.1 to 17.9) 11.8 (8.8 to 14.7) 14.3 (12.2 to 16.4)	18.5 (16.7 to 20.4) 18.3 (14.8 to 21.9) 13.0 (8.9 to 17.1) 20.6 (17.0 to 24.2) 21.4 (16.5 to 26.4)	16.9 (14.2 to 19.5) 17.5 (12.5 to 22.5) 12.6 (7.5 to 17.7) 18.1 (12.6 to 23.6) 18.9	0.3 0.5 0.14) 0.0 0.4 0.4 0.5 0.5 0.5 0.1
19.2 17.8 17.8 17.8 17.8 (14.1 to 21.5) 17.8 (14.1 to 21.4) 20.8 (14.1 to 21.4) (14.1 to 21.4) (14.1 to 21.4) (16.5 to 22.9) (16.5 to 22.9) (0.27) (0.27) (17.7 to 20.9) (13.1 to 25.1)	to 24.7) to 26.5) to 26.7) to 26.8) to 32.0) to 32.0)	21.9 (18.7 to 25.1) 19.1 (13.9 to 24.4) 26.8 (20.0 to 33.7) (21.3 21.3 (15.3 to 27.2) 23.9 23.9 (14.3 to 33.5) 4.9 (0.57)	0.3 0.22) 0.2 0.51) 0.2 0.2 0.2 0.5 0.2 0.2 0.2 0.2 0.2 0.2	13.6 (12.3 to 14.9) 12.4 (10.2 to 14.6) 13.8 (8.1 to 19.6) 14.5 (11.4 to 17.7) 14.3 (11.2 to 16.4) 14.3 2.9	13.3 (11.9 to 14.6) 12.8 (10.5 to 15.1) 11.5 (5.1 to 17.9) 11.8 (5.1 to 17.9) 11.8 (8.8 to 14.7) 14.3 (12.2 to 16.4)	18.5 (16.7 to 20.4) 18.3 (14.8 to 21.9) 13.0 (8.9 to 17.1) 20.6 (17.0 to 24.2) 21.4	16.9 (14.2 to 19.5) 17.5 (12.5 to 22.5) 12.6 (7.5 to 17.7) 18.1 (12.6 to 23.6) 18.9 18.9	0.3 (0.24) 0.5 0.14) 0.4 (0.32) 0.5 0.5 0.1
(17.7 to 20.8) 17.8 (14.1 to 21.5) 17.8 (14.1 to 21.4) (14.1 to 21.4) (14.1 to 21.4) (14.1 to 21.4) (18.0 to 23.5) (18.0 to 23.5) (19.7 to 20.9) (17.7 to 20.9) (13.1 to 25.1) (13.1 to 25.1) (1	 to 24.7) to 26.5) to 26.3) to 26.8) to 32.0) to 24.6) 	(18.7 to 25.1) 19.1 213.9 to 24.4) 26.8 (20.0 to 33.7) 21.3 21.3 21.3 (15.3 to 27.2) 23.9 23.9 23.9 23.9 23.5 (14.3 to 33.5) 4.9 (0.57)	(0.22) 0.2 0.7 0.7 0.2 0.2 0.5 0.5 0.5 0.2 0.2 (0.46)	(12.3 to 14.9) 12.4 (10.2 to 14.6) 13.8 (8.1 to 19.6) 14.5 (11.4 to 17.7) 14.3 (11.2 to 16.4) 2.9	(11.9 to 14.6) 12.8 (10.5 to 15.1) 11.5 (5.1 to 17.9) 11.8 (8.8 to 14.7) 14.3 (12.2 to 16.4)	(16.7 to 20.4) 18.3 (14.8 to 21.9) 13.0 (8.9 to 17.1) 20.6 (17.0 to 24.2) 21.4 (16.5 to 26.4)	(14.2 to 19.5) 17.5 (12.5 to 22.5) 12.6 (7.5 to 17.7) 18.1 (12.6 to 23.6) 18.9 18.9	(0.24) 0.5 0.14) 0.0 0.4 0.4 (0.32) 0.5 0.5
17.8 17.8 (14.1 to 21.5) 17.8 (14.1 to 21.4) 20.8 (14.1 to 21.4) 20.8 (18.0 to 23.5) ations 19.7 (16.5 to 22.9) (16.5 to 22.9) (16.5 to 22.9) (16.7 to 20.9) onal 19.1 (17.7 to 20.9) (13.1 to 25.1)	to 26.5) to 26.7) to 26.8) to 26.8) to 26.8) to 24.6)	19.1 (13.9 to 24.4) 26.8 (20.0 to 33.7) (21.3 21.3 (15.3 to 27.2) 23.9 (14.3 to 33.5) 4.9 (0.57)	0.2 0.7 0.7 0.2 0.2 0.5 0.5 0.2 0.2 0.2 0.2	12.4 (10.2 to 14.6) 13.8 (8.1 to 19.6) 14.5 (11.4 to 17.7) 14.3 (12.2 to 16.4) 2.9	12.8 (10.5 to 15.1) 11.5 (5.1 to 17.9) 11.8 (8.8 to 14.7) 14.3 (12.2 to 16.4)	18.3 (14.8 to 21.9) 13.0 (8.9 to 17.1) 20.6 (17.0 to 24.2) 21.4 (16.5 to 26.4)	17.5 (12.5 to 22.5) 12.6 (7.5 to 17.7) 18.1 (12.6 to 23.6) 18.9 18.9	0.5 (0.14) 0.0 0.4 0.4 (0.32) 0.5 0.5
(14.1 to 21.5) 17.8 (14.1 to 21.4) 20.8 (18.0 to 23.5) 20.8 (18.0 to 23.5) (18.0 to 23.5) (18.0 to 23.5) (18.0 to 23.5) (18.1 to 22.9) (17.7 to 20.9) (17.7 to 20.9) 0 onal 19.1 (13.1 to 25.1)	(10 26.5) (10 26.7) (10 26.8) (10 26.8) (10 26.8) (10 24.6) (10 24.6)	(13.9 to 24.4) 26.8 (20.0 to 33.7) 21.3 21.3 (15.3 to 27.2) 23.9 (14.3 to 33.5) 4.9 (0.57)	(0.51) 0.7 0.2 0.2 0.5 0.5 (0.23) 0.2 (0.46)	(10.2 to 14.6) 13.8 (8.1 to 19.6) 14.5 (11.4 to 17.7) 14.3 (12.2 to 16.4) 2.9	(10.5 to 15.1) 11.5 (5.1 to 17.9) 11.8 (8.8 to 14.7) 14.3 (12.2 to 16.4)	(14.8 to 21.9) 13.0 (8.9 to 17.1) 20.6 (17.0 to 24.2) 21.4 (16.5 to 26.4)	(12.5 to 22.5) 12.6 (7.5 to 17.7) 18.1 (12.6 to 23.6) 18.9 18.9	(0.14) 0.0 0.4 0.4 (0.32) 0.5 (0.25) 0.1
17.8 (14.1 to 21.4) 20.8 (18.0 to 23.5) 20.8 (18.0 to 23.5) (18.5 to 22.9) (16.5 to 22.9) (16.5 to 22.9) (16.5 to 22.9) (17.7 to 20.9) (17.7 to 20.9) (13.1 to 25.1) (13.1 to 25.1)	to 26.7) to 26.8) to 32.0) to 32.0)	26.8 (20.0 to 33.7) 21.3 (15.3 to 27.2) 23.9 (14.3 to 33.5) 4.9 (0.57)	0.7 0.2 0.5 0.5 0.5 0.2 0.2 0.2 0.2 0.2	13.8 (8.1 to 19.6) 14.5 (11.4 to 17.7) 14.3 (12.2 to 16.4) 2.9	11.5 (5.1 to 17.9) 11.8 (8.8 to 14.7) 14.3 (12.2 to 16.4)	13.0 (8.9 to 17.1) 20.6 (17.0 to 24.2) 21.4 (16.5 to 26.4)	12.6 (7.5 to 17.7) 18.1 (12.6 to 23.6) 18.9 18.9	0.0 (0.81) 0.4 0.5 (0.32) 0.5 0.1
(14.1 to 21.4) 20.8 (18.0 to 23.5) (18.0 to 23.5) (16.5 to 22.9) (16.5 to 22.9) (16.5 to 22.9) (16.5 to 22.9) (16.5 to 22.9) (17.7 to 20.9) (17.7 to 20.9) (13.1 to 25.1) (13.1 to 25.1)	(to 26.7) (to 26.8) (to 32.0) (to 32.0) (to 24.6)	(20.0 to 33.7) 21.3 (15.3 to 27.2) 23.9 (14.3 to 33.5) 4.9 (0.57)	(0.02) 0.2 0.5 0.5 0.2 (0.23) 0.2	(8.1 to 19.6) 14.5 (11.4 to 17.7) 14.3 (12.2 to 16.4) 2.9	(5.1 to 17.9) 11.8 (8.8 to 14.7) 14.3	(8.9 to 17.1) 20.6 (17.0 to 24.2) 21.4 (16.5 to 26.4)	(7.5 to 17.7) 18.1 (12.6 to 23.6) 18.9 13.9	(0.81) 0.4 (0.32) 0.5 (0.25) 0.1
20.8 (18.0 to 23.5) (18.0 to 23.5) (16.5 to 22.9) (16.5 to 22.9) (16.5 to 22.9) (16.5 to 22.9) (16.5 to 22.9) (17.7 to 20.9) (13.1 to 25.1) (13.1 to 25.1)	(to 26.8) (to 32.0) (to 24.6)	21.3 (15.3 to 27.2) 23.9 (14.3 to 33.5) 4.9 (0.57)	0.2 0.56) 0.5 0.2 0.2 (0.46)	14.5 (11.4 to 17.7) 14.3 (12.2 to 16.4) 2.9	11.8 (8.8 to 14.7) 14.3 (12.2 to 16.4)	20.6 (17.0 to 24.2) 21.4 (16.5 to 26.4)	18.1 (12.6 to 23.6) 18.9 (12.6 to 25.2)	0.4 (0.32) 0.5 0.1
(18.0 to 23.5) ations 19.7 (16.5 to 22.9) (16.5 to 22.9) (0.27) (0.27) (0.27) (17.7 to 20.9) onal 19.1 (13.1 to 25.1)	to 26.8) to 32.0) to 24.6)	(15.3 to 27.2) 23.9 (14.3 to 33.5) 4.9 (0.57)	(0.56) 0.5 0.23) 0.2 (0.46)	(11.4 to 17.7) 14.3 (12.2 to 16.4)	(8.8 to 14.7) 14.3 (12 2 to 16 4)	(17.0 to 24.2) 21.4 (16.5 to 26.4)	(12.6 to 23.6) 18.9 (12 6 to 25 2)	(0.32) 0.5 (0.25) 0.1
ations 19.7 (16.5 to 22.9) (16.5 to 22.9) (0.27) (0.27) (0.27) 19.3 (17.7 to 20.9) (13.1 to 25.1) (13.1 to 25.1)) to 32.0))) to 24.6)	23.9 (14.3 to 33.5) 4.9 (0.57)	0.5 (0.23) 0.2 (0.46)	14.3 (12.2 to 16.4) 2 q	14.3 (12.2 to 16.4)	21.4 (16.5 to 26.4)	18.9 (12 6 to 25 2)	0.5 (0.25) 0.1
(16.5 to 22.9) 3.4 (0.27) 19.3 (17.7 to 20.9) 0nal 19.1 (13.1 to 25.1)	(to 32.0) () to 24.6)	(14.3 to 33.5) 4.9 (0.57)	(0.23) 0.2 (0.46)	(12.2 to 16.4) 2.9	(12 2 to 16 4)	(16.5 to 26.4)	(10 G to 05 0)	(0.25) 0.1
le) 3.4 (0.27) (19.3 (17.7 to 20.9) (19.1 (13.1 to 25.1) () to 24.6)	4.9 (0.57)	0.2 (0.46)	00	1	-	1-	0.1
(0.27) (0.27) (0.27) (0.27) (17.7 to 20.9) (17.7 to 20.9) (13.1 to 25.1) (13.1 to	() to 24.6)	(0.57)	(0.46)	i	2.0	5.8	2.5	
19.3 (17.7 to 20.9) (19.1 (13.1 to 25.1) (to 24.6)			(0.12)	(0.49)	(0.48)	(0.71)	(0.83)
19.3 (17.7 to 20.9) (professional 19.1 (13.1 to 25.1) (to 24.6)							
(17.7 to 20.9) (19.1 (13.1 to 25.1) ((20.3 to 24.6) (22.1	0.3	13.6	12.9	18.1	17.0	0.3
19.1 (13.1 to 25.1) ((18.9 to 25.4)	(0.20)	(12.3 to 15.0)	(11.5 to 14.2)	(16.3 to 20.0)	(14.3 to 19.7)	(0.21)
(13.1 to 25.1) (25.6	15.4	-0.1	15.0	20.5	19.3	14.0	-0.2
	(18.4 to 32.9) ((5.9 to 24.8)	(0.82)	(4.7 to 25.2)	(10.9 to 30.1)	(12.0 to 26.7)	(1.7 to 26.3)	(0.71)
•	20.0	18.8	0.1	9.9	11.7	18.7	16.9	0.6
(15.0 to 21.1) (to 23.7)	(13.4 to 24.2)	(0.44)	(7.4 to 12.3)	(9.2 to 14.3)	(15.2 to 22.1)	(12.4 to 21.4)	(0.15)
		23.5	0.5	15.1	12.1	18.5	15.6	0.2
(13.0 to 23.2) (to 29.1)	(12.7 to 34.3)	(0.14)	(12.7 to 17.5)	(9.8 to 14.4)	(15.2 to 21.8)	(10.9 to 20.3)	(0.58)
•	••	28.8	0.8	14.2	14.1	17.5	20.5	0.5
to 22.3) (to 27.7) ((21.4 to 36.1)	(0.08)	(9.8 to 18.7)	(9.4 to 18.8)	(10.9 to 24.2)	(9.2 to 31.7)	(0.02)
		23.0	0.1	12.1	14.6	16.4	20.1	0.6
(17.6 to 26.5) ((16.8 to 27.9) ((15.3 to 30.7)	(0.40)	(9.0 to 15.3)	(11.4 to 17.8)	(12.2 to 20.6)	(13.5 to 26.6)	(0.009)
		30.1	1.1	16.3	14.9	20.7	21.9	0.5
(8.2 to 22.1) (9.2 to 23.9)	(12.8 to 32.0) ((18.1 to 42.2)	(0.01)	(12.4 to 20.2)	(10.1 to 19.7)	(13.1 to 28.4)	(15.0 to 28.9)	(0.10)
SII (p value) 2.5 1.0	1.3	13.9	0.8	4.6	2.6	-1.4	4.7	0.0
(0.38) (0.62)	(0.71) ((0.05)	(0.21)	(0.26)	(0.44)	(0.49)	(0.16)	(0.92)
Hypertension (uncontrolled) defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, irrespective of treatment	ure ≥140 mm Hg o	r diastolic blood p	oressure ≥90	mm Hg, irrespec	ctive of treatment.			
The game rower minit has been set to zero.	ing Dinamap monite	ors and then conv	rerted to Omr	on monitor readir	ngs.			
∔Merged data set. EEducational qualification cataoorias – lavel 3–daorea lavel or above: lavel 3–intermediate: lavel 1–statutory school leaving: no qualifications		intermediate: le	1	pavinal leaving	·			

	Men					Women				
	Proportion (%) (95% CI)	() (95% CI)			Trend	Proportion (%) (95% CI)	() (95% CI)			Trend
	1995	1998	2003	2008/2009*	(p value)	1995	1998	2003	2008/2009*	(p value)
Hypercholesterolaemia †	iia†									
All	79.6	69.5	71.8	63.8	-1.0 (0.14)	74.1	65.8	69.3	66.3	-0.4 (0.40)
	(78.1 to 81.1)	(67.7 to 71.3)	(69.4 to 74.2)	(59.9 to 67.8)		(72.6 to 75.7)	(64.0 to 67.7)	(67.0 to 71.5)	(62.6 to 70.0)	
Level 3	80.7	69.1	72.2	60.6	-1.2 (0.13)	72.3	66.7	67.4	74.2	0.2 (0.66)
	(77.3 to 84.2)	(65.1 to 73.2)	(68.0 to 76.5)	(53.7 to 67.5)		(69.5 to 75.1)	(63.5 to 70.0)	(63.3 to 71.5)	(68.5 to 80.0)	
Level 2	/9.3 /70.4 ± 60 t)	69.9 (50.4 t- 70 r)	/1.5 (2011: 70.0)	65.0 (F7.6 ±- 70.1)	-0.9 (0.14)	/5.4 (74.0 ± 70 ±)	66.9 (50.4 ±- 74.0)	63.9 (F0.0 ± - 00 ±)	65.9 (50.0 ± 70.0)	-0.6 (0.28)
	(76.7 to 82.5) 70.2	(66.4 to 73.5) 60 E	(66.4 to /6.6) 72 7	(1.27 01 6.73) 68 0	06 (0 31)	(/1.2 to /9./) 73.2	(62.4 to 71.3) 63 A	(58.8 to 69.1) 72 0	(59.0 to 72.8) 57 a	08 (035)
	(76.7 to 81.8)	(66.2 to 72.8)	(68.5 to 76.9)	(58.5 to 79.3)		(70.0 to 76.4)	(59.5 to 67.3)	(67.6 to 76.4)	(49.9 to 66.0)	
No qualifications	80.3	69.5	67.7	70.2	-0.6 (0.36)	78.1	70.0	75.1	65.6	-0.7 (0.26)
	(77.2 to 83.4)	(65.3 to 73.8)	(56.1 to 79.4)	(58.8 to 81.5)		(75.1 to 81.1)	(66.1 to 73.9)	(69.6 to 80.6)	(55.3 to 75.9)	
SII (p value)			-3.8 (0.41)	13.3 (0.006)	0.9 (0.31)	8.0 (0.12)	3.8 (0.56)	11.6 (0.20)	-16.9 (0.23)	-1.6 (0.28)
Low HDL cholesterol										
(direct method)‡										
All	1	1	6.6	7.1	0.1	1	1	9.3	8.4	-0.2
			(5.2 to 8.0)	(4.9 to 9.3)				(7.7 to 10.8)	(6.0 to 10.7)	
Level 3	I	1	3.0	5.4	0.4	1	1	6.9	4.3	-0.5
			(1.2 to 4.7)	(2.2 to 8.5)				(4.4 to 9.3)	(1.3 to 7.3)	
Level 2	1	1	7.4	7.6	0.0	1	1	7.9	8.9	0.2
			(4.2 to 10.6)	(3.1 to 12.0)				(4.8 to 11.0)	(4.3 to 13.5)	
Level 1	I	I		6.1	-0.4	1	I	10.8	11.6	0.1
			(5.6 to 11.1)	(1.5 to 10.6)				(7.6 to 14.0)	(5.6 to 17.6)	
No qualifications	1	I	8.3	14.6	1.2	1	1	10.8	12.8	0.4
			(3.6 to 12.9)	(5.4 to 23.8)				(7.1 to 14.6)	(6.0 to 19.6)	
SII			7.5	7.0	-0.1			6.1	11.9	1.1
(p value)			(0.11)	(0.32)				(0.05)	(0.01)	
Educational qualification categories = level 3—degree level or above; level 2—intermediate; level 1—statutory school leaving; no qualifications.	r categories = le	vel 3degree leve	el or above; level	2	level 1-statuto	ry school leaving;	no qualifications.		croton bac about to	
were the same.										
‡Low HDL cholesterol: men <1.0 mmol/l, women <1.2 mmol/l. Time trends not evaluated as only two time points. HDL cholesterol cr Health Surveys using a cholesterol oxidase method and analyses relating to these surveys are reproduced in supplementary table 1. HDL, high-density lipoprotein; SII, slope index of inequality.	men <1.0 mmol/ cholesterol oxida otein; SII, slope	l, women <1.2 mn ase method and ar index of inequality	nol/l. Time trends nalyses relating to	not evaluated as these surveys ar	only two time p re reproduced i	ooints. HDL cholee n supplementary t	sterol concentratic able 1.	trends not evaluated as only two time points. HDL cholesterol concentration was determined in the 1995 and 1998 Scottish ating to these surveys are reproduced in supplementary table 1.	l in the 1995 and	1998 Scotti

Gender-specific, age-standardised prevalences for hypercholesterolaemia and low-serum HDL cholesterol concentration in five Scottish Health Surveys 1995, 1998, 2003 and 2008/2009 stratified by occupational social class Table 7

	Men					Women				
	Proportion (%) (95% CI)*	6) (95% CI)*			Trend	Proportion (%) (95% CI)*	(95% CI)*			Trend
	1995	1998	2003	2008/2009	(p value)	1995	1998	2003	2008/2009†	(p value)
Hypercholesterolaemia‡	mia‡									
All	79.4	69.5 2010 - 100	71.8	64.6	-0.9 (0.16)	74.2	65.6 2000 - 2000	69.0	66.9 (20.0 - 2 - 2	-0.4 (0.45)
	(77.9 to 80.9)	(67.6 to 71.3)	(69.4 to /4.1) 70.4	(60.6 to 68.5)		(72.6 to 75.8)	(63.8 to 67.5)	(66.7 to 71.3) 70.6	(63.0 to /0./)	
I, proressional	/0.1 (70.3 to 82 0)	72.5 (66.1 to 78.8)	/U.I (62.3 to 77.8)	66.4 (53 1 to 79 7)	(IN) (N)-	81.0 (74.1 to 89.0)	/0.0 (61.2 to 78.9)	/0.6 (60 5 to 80 7)	65.9 (54.8 tn 76 9)	-1.U (U.16)
II, managerial	82.1	68.0	72.7	(55.8 65.8	-0.9 (0.27)	70.5		64.0	68.3	-0.1 (0.75)
)	(79.3 to 84.9)	(64.3 to 71.7)	(68.5 to 76.9)	(58.7 to 73.0)	~	(67.2 to 73.9)	(62.1 to 68.9)	(59.9 to 68.1)	(62.6 to 73.9)	
III, skilled NM	80.3	67.1	65.0	59.5	-1.3 (0.10)	75.7		68.4	66.0	-0.4 (0.53)
	(76.1 to 84.6)	(61.3 to 72.8)	(56.9 to 73.1)	(48.8 to 70.2)		(73.2 to 78.2)	to 66.2)	(64.3 to 72.5)	(58.7 to 73.4)	
III, skilled M	77.9 (75.4 to 80.5)	70.3 (67.2 to 73.4)	74.6 (70.3 to 78.9)	69.9 (62 8 to 77 0)	-0.4 (0.39)	77.0 (71 3 to 82 7)	65.9 (59.6 to 72.2)	83.5 (75.8 to 91.2)	/3.3 (63.5 to 83.1)	0.2 (0.85)
IV, partly skilled	79.8	72.2	68.6	54.4	-1.8 (0.02)	75.6	(33.0 10 1 E.E.) 69.0	75.1	66.7	-0.4 (0.41)
-	(75.7 to 84.0)	(67.8 to 76.6)	(62.1 to 75.1)	(45.3 to 63.6)	~	(71.9 to 79.4)	(64.7 to 73.3)	(69.9 to 80.2)	(55.4 to 77.9)	~
V, unskilled	80.4	68.9	69.8	56.6	-1.5 (0.08)	76.2		64.1	75.0	0.0 (0.98)
	(73.8 to 87.1)	(59.5 to 78.3)	(59.8 to 79.8)	(43.2 to 70.0)		(70.6 to 81.9)	(59.2 to 74.1)	(55.7 to 72.5)	(60.9 to 89.2)	
SII (p value)	-1.7 (0.63)	3.1 (0.33)	-0.8 (0.89)	-8.0 (0.42)	-0.6 (0.27)	5.6 (0.21)	2.9 (0.48)	11.1 (0.26)	1.3 (0.77)	-0.1 (0.83)
Low HDL cholesterol	0									
(airect methoa)S			0	, 1				0	Ţ	0
AII	I	1	6.6 (۲.۲ ۲.۲ - ۲.۲	L.0	I	1	9.2 	/.4 /	-0.3
			(5.2 to 8.0)	(4.8 to 9.3)				(7.6 to 10.7)	(5.2 to 9.7)	
l, professional	1	I	7.3	8.8	0.3	I	1	3.6	5.5	0.3
:			(2.8 to 11.7)	(2.3 to 15.3)	1			(0 to 8.0)	(0 to 11.5)	1
ll, managerial	I	1	3.1	5.7	0.5	I	1	6.9	4.3	-0.5
			(1.3 to 4.9)	(2.0 to 9.4)	Ċ			(4.5 to 9.3)	(1.6 to 7.0)	Ċ
		I	4.4 (0.4 to 8.4)	3.1 (0 to 7 0)	0.2	I	I	11.2 (8 1 to 14.3)	9.0 (4 9 to 14 7)	0.0
III, skilled M	Ι	I	9.7	10.9	0.2	I	Ι	6.9	6.0	-0.2
			(6.6 to 12.7)	(5.6 to 16.3)				(2.0 to 11.9)	(0 to 12.8)	
IV, partly skilled	1	I	8.5	3.9	-0.8	I	1	11.2	11.3	0.0
			(4.4 to 12.6)	(0.1 to 7.8)				(7.3 to 15.1)	(4.4 to 18.3)	
V, unskilled	1	1	12.7	2.4	-1.9	I	1	11.5	5.0	-1.2
			(4.5 to 20.9)	(0 to 7.3)				(4.7 to 18.3)	(0 to 12.4)	
SII (p value)			8.0 (0.09)	-0.5 (0.93)	-1.6			6.7 (0.07)	7.9 (0.09)	0.2
Time trends not evaluated as only two time points. HDL cholesterol concentration was determined in the 1995 and 1998 Scottish Health Surveys using a cholesterol oxidase method and analyses relating to these surveys are reproduced in supplementary table 2. *Negative lower limit has been set to zero. †Merged data set.	ated as only two t ys are reproduce las been set to ze	ime points. HDL clead in supplementatero.	nolesterol concent y table 2.	ation was determi	ined in the 1995	i and 1998 Scottisl	ר Health Surveys ו	using a cholesterc	ol oxidase method	and analyses
‡Total cholesterol serum concentration ≥5.0 mmol/l. A different laboratory completed analyses in 1995 than in later surveys. Different analysers were used but methods and reference standards	um concentration	≥5.0 mmol/l. A di	fferent laboratory o	completed analyse	s in 1995 than	in later surveys. D	ifferent analysers	were used but me	ethods and refere	ice standards
<pre>\$Low HDL cholesterol: men<1.0 mmol/l, women <1.2 mmol/l. HDL, high-density lipoprotein; M, manual; NM, non-manual; SII, slope index of inequality.</pre>	: men<1.0 mmol/ protein; M, manu	/l, women <1.2 mr ial; NM, non-manu	nol/I. al; SII, slope inde>	of inequality.						

Cardiovascular biomarker patterns

The threshold fibrinogen plasma concentration for the upper quintile increased from 3.1 g/l in 1998 to 3.4 g/l in 2008/2009 for men and from 3.3 to 3.6 g/l for women (tables 8 and 9). In 2008/2009, the threshold C reactive protein serum concentration for the highest quintile had increased to 3.71 mg/l for men and 4.80 mg/l for women (tables 8 and 9). For both inflammatory risk markers, socioeconomic inequalities existed that appeared greater in magnitude for men than for women.

DISCUSSION

In Scotland, between 1995 and 2009, the changes in the prevalence of three major risk factors for CVD present a mixed story. Overall, prevalences have increased for obesity (including central obesity), stagnated for hypertension and decreased for hypercholesterolaemia. Many of the biomarkers considered in this study had socioeconomic gradients that persisted throughout the surveys. Considering this intransigence (with the exception of total cholesterol), it is perhaps not surprising that behavioural risk factors have also changed little over the same period in Scotland.¹³

Consistent with the rest of the developed world the Scottish population is becoming more obese.²⁶ The larger increase in the prevalence of women with excessive WC and WHR could suggest that the rise in obesity among women has been particularly manifested as an increase in central adiposity. For all three measures of adiposity, absolute inequalities existed for both genders. However, there were some inconsistencies by social class, particularly for men. Greater inequalities for women have been observed elsewhere.^{27–30} The inequalities remained unchanged over time, even widening for women by WHR when stratified by education, similar to findings in other European countries.^{27 28} It should be noted that for all the biomarkers considered in this study, precise comparison with other studies is difficult because of different definitions, sample demographics and study design.

An overall declining trend in mean systolic blood pressure in the developed world, and in particular Western Europe, has been identified.³¹ In contrast, although not directly comparable, our study identified that the prevalence of hypertension remained relatively static, with the hint of an increase, in Scotland. Levelling of declines, or even an increase in the case of England, have been identified in other countries over similar time periods.³²⁻³⁴ Inequalities have been reported for blood pressure in other countries³² ³⁵ and in the past for Scotland among just women.³⁶ The static trend in Scotland may be in part a consequence of improved hypertension management and medication, as in England,³⁴ along with reduced behavioural risk factors such as increased physical activity and reduced discretional salt use¹³ being counteracted by increased obesity trends and consumption of high salt content processed foods.³⁷

The good news of a modest decline in hypercholesterolaemia in this study concurs with findings for the developed world.³⁸ This is tempered by the stark fact that in 2008/2009, the majority of respondents still had excessive serum concentrations of total cholesterol. Inequalities existed for women but these were less apparent by 2008/2009, while for men, there were limited social gradients. A lack of socioeconomic inequalities for total cholesterol is a common finding.^{32 33} Å social class differential has been reported for women for hypercholesterolaemia in Scotland in the past³⁶ and elsewhere in the UK.³⁹ Whereas historically for men in Scotland, high cholesterol has been associated with nonmanual social class.³⁶ The decline in hypercholesterolaemia prevalence is probably due to changes in health behaviours, for example, a decrease in saturated fats consumption, along with the increased use of lipidlowering drugs over the surveys, their use being more prevalent in more disadvantaged groups, particularly in the 2008/2009 surveys.

The proportion with low HDL cholesterol concentration changed little between 2003 and 2008/2009. Within each of the survey years, stronger social gradients existed for women than for men with the disadvantaged having a higher prevalence of low HDL cholesterol. Socioeconomic gradients in this direction have been identified for men and women,⁴⁰ just women^{41,42} and appeared to be absent for both sexes.³⁰ Elevated levels of C reactive protein and fibrinogen are associated with an increased risk of CHD but are considered to be markers as they are unlikely to be causal.^{43 44} The absence of defined clinical thresholds indicating higher risk of CHD, plus skewed distributions, prompted the use of upper quintiles; some have considered this to represent 'high risk'.45 The threshold demarking the upper quintile was always higher for women, as seen in other studies,⁴⁶ and the increase for both genders across the surveys would imply a shift to the right for at least some of the population. Much of the social gradient in these inflammatory markers, as seen in this study, can be explained by risk factors such as smoking, adiposity, cholesterol and physical activity.^{46–48} These risk factors are socially patterned in the SHeSs, although the latter two principally for women.¹³

One of this study's strengths is the use of data from nationally representative surveys. We also recognise a number of limitations. Only individuals living in private households were surveyed, and the declining response levels in these surveys are of concern, possibly introducing bias. This problem is common across surveys in general. The clustered design of the sampling in this study will lead to larger standard errors than those from a simple random sample of the same size because members of a cluster are more likely to resemble one another. Nevertheless, the effect of clustering was reduced as a high percentage of all possible postcode sectors were included in the SHeSs. A switch to sampling multiple adults within households from 2003 probably

đ	roport	ion in highest q	Proportion in highest quintile (%) (95% (CI)	Trend	Propol	Proportion in highest quintile (%) (95% CI)	uintile (%) (95%	CI)	Trend
1	1995	1998	2003	2008/2009*	(p value)	1995	1998	2003	2008/2009*	(p value)
Fibrinogen Threshold for highest	est	>3.10	>3.30	>3.40			>3.30	>3.60	>3.60	
quintile (g/l)† – –	1	18.6	18.4	19.0	0.0 (0.52)	Ι	18.1	17.9	18.9	0.1 (0.40)
		(17.0 to 20.2)	(16.2 to 20.6)	(15.5 to 22.5)	03 (0 54)		(16.4 to 19.7) 16.5	(15.8 to 20.1) 15.5	(15.4 to 22.3)	121010
		9.9 (6.9 to 12.9)	(10.4 to 18.0)	(7.6 to 18.3)	(+0.0) 0.0	I	(13.7 to 19.3)	(11.7 to 19.3)	(7.3 to 17.3)	-0.4 (0.17)
Level 2 —		18.7	18.0	18.7	0.0 (0.94)	I	14.5	12.7	18.8	0.4 (0.50)
		(15.2 to 22.1)	(12.7 to 23.3)	(11.5 to 25.9)			(9.1 to 19.8)	(8.1 to 17.4)	(11.9 to 25.7)	
Level 1 –	1	19.0	19.7	22.1	U.3 (U.31)	I	19.1	21.0	27.0	0.8 (0.10)
UN N	,	(16.6 to 22.7) 24.9	(15.7 to 23.7) 21.1	(15.4 to 30.1) 27.5	0.3 (0.72)	I	(15.3 to 22.9) 20.4	(16.8 to 25.3) 20.1	(18.8 to 35.3) 20.3	0.0 (0.84)
qualifications		(21.0 to 28.9)	(15.9 to 26.3)	(14.9 to 40.1)			(17.1 to 23.7)	(14.8 to 25.4)	(11.8 to 28.8)	
SII (p value)		16.9 (0.06)	9.2 (0.03)	17.9 (0.004)	0.1 (0.91)		6.4 (0.17)	8.7 (0.27)	16.3 (0.18)	1.0 (0.17)
C reactive protein										
Threshold for highest	est	>3.40	>3.50	>3.71			>4.30	>4.80	>4.80	
quintile										
(mg/l)										
All –	1	19.9	19.8	18.8	-0.1 (0.23)	Ι	20.0	19.6 (12 - 1 - 2 - 2)	19.6	0.0 (0.42)
		(18.3 to 21.5)	(17.6 to 21.9)	(15.7 to 21.9)			(18.3 to 21.6)	(17.5 to 21.6)	(16.3 to 22.9)	
Level 3 –		13.0 /0.0 to 16 1/	16.6 /12.0 to 20.2)	11.9 /7 2 to 16 6)	-0.1 (0.84)	I	15.8 /12 1 to 10 6/	14.7 (11.0 to 10.0)	15.2 (10.0 to 20.4)	-0.1 (0.62)
– C ave 2		19.4	15.9 10 20.07	18.7	-0 1 (0 89)	I	19.3	14.0	17.3	(22 0) 2 0-
		(15.9 to 22.9)	(11.1 to 20.8)	(12.4 to 24.9)			(13.2 to 25.3)	(9.7 to 18.4)	(11.1 to 23.5)	
Level 1 –	_1_	20.8	19.8	23.0	0.2 (0.52)	Ι	21.8	23.3	24.3	0.2 (0.08)
		(17.9 to 23.7)	(16.1 to 23.5)	(16.7 to 29.2)			(18.0 to 25.7)	(19.1 to 27.4)	(16.8 to 31.8)	
No –	1-	27.4	25.8	32.9	0.5 (0.45)	Ι	23.1	23.6	23.2	0.0 (0.92)
qualifications		(23.2 to 31.5)	(19.9 to 31.7)	(21.0 to 44.9)			(19.7 to 26.4)	(18.1 to 29.2)	(15.6 to 30.7)	
SII (p value)		16.4 (0.04)	11.0 (0.12)	24.2 (0.03)	0.8 (0.59)		10.7 (0.03)	14.3 (0.11)	12.9 (0.08)	0.2 (0.61)

Table 9 Gender-specific, age-standardised prevalences for elevated plasma fibrinogen and serum C reactive protein concentrations in five Scottish Health Surveys 1995,

	Men					Women	-			
	Propol	rtion in highest (Proportion in highest quintile (%) (95% Cl)*	cI)*	Trend			Proportion in highest quintile (%) (95% CI)*	%) (95% CI)*	Trend
	1995	1998	2003	2008/2009†	(p value)	1995	1998	2003	2008/2009†	(p value)
Fibrinogen Threshold for top quintile	uintile	>3.10	>3.30	>3.40			>3.30	>3.60	>3.60	
All	Ι	18.8	18.3	19.1	0.0 (0.75)	I	18.0	17.9	19.4	0.1 (0.35)
-		(17.1 to 20.5)	(16.1 to 20.5)	(15.6 to 22.6)			(16.3 to 19.7)	(15.8 to 20.1)	(15.9 to 23.0)	
I, protessional		8.5 /2 7 to 12 2/	14.5 /8 2 to 20 0/	14.1 /2 8 to 24 4)	0.5 (0.39)	I	23.3 (15 8 to 30 7)	10.9 /3 3 to 18 E/	18.4 /E 0 to 21 7)	-0.4 (0.76)
II, managerial	I	(s./ 10 13.3) 14.2	(0.2 (0 20.3) 17.6	(3.0 IU 24.4) 13.2	-0.1 (0.84)	I	(13.0 10 30.7) 14.1	(3.3 (0 10.3) 17.4	(5.0 (0.51.7) 15.9	0.2 (0.64)
		(11.3 to 17.0)	(13.7 to 21.5)	(7.3 to 19.0)			(11.2 to 17)	(13.5 to 21.3)	(11.1 to 20.8)	
III, skilled NM	I	23.8 (18.0 to 29.5)	7.5 (2 8 to 12 2)	16.8 (8.0 to 25.7)	-0.6 (0.74)	I	19.5 (16.5 to 22.6)	16.3 (12 6 to 20 1)	27.0 (19.3 to 34.6)	0.7 (0.51)
III, skilled M	Ι	20.4	16.9	20.5	0.0 (0.97)	I	19.8	20.9	13.8	-0.6 (0.41)
		(17.6 to 23.2)	(13.0 to 20.8)	(14.6 to 26.4)			(14.3 to 25.3)	(12.1 to 29.8)	(3.2 to 24.4)	
IV, partly skilled	I	23.6	28.5	16.5 /6.4 to 04.6/	-0.7 (0.58)	I	19.9	20.2	21.0	0.1 (0.15)
V. unskilled	I	(18.9 to 28.2) 20.0	(22.1 10 34.9) 25.2	(o.4 lu z4.0) 39.6	1.9 (0.15)	I	(15.9 10 とう.9) 19.8	(15.0 10 25.3) 23.9	(11.3 to 30.7) 13.0	-0.7 (0.56)
		(11.0 to 29.1)	(12.7 to 37.7)	(24.8 to 54.4)			(13.6 to 26.1)	(15.2 to 32.7)	(1.0 to 25.1)	
SII (p value)		13.4 (0.04)	11.5 (0.23)	13.6 (0.15)	0.0 (0.95)		6.4 (0.15)	7.3 (0.08)	7.1 (0.45)	0.1 (0.51)
C reactive protein										
Threshold for top quintile	luintile	>3.40	>3.50	>3.71			>4.30	>4.80	>4.80	
All	I	19.8	19.5	18.9	-0.1 (0.08)	I	20.0	19.4	19.5	-0.1 (0.41)
		(18.1 to 21.4)	(17.3 to 21.6)	(15.8 to 22.1)			(18.3 to 21.7)	(17.3 to 21.5)	(16.1 to 22.8)	
I, professional		5.9	17.0	4.1	-0.2 (0.90)	1	7.5	16.8	12.2	0.4 (0.68)
		(2.4 to 9.5)	(10.6 to 23.5)	(0 to 10.1)			(1.6 to 13.4)	(9.2 to 24.4)	(2.2 to 22.2)	
II, manageriai	I	15.3 (12.5 to 18.2)	18./ (14.9 to 22.5)	19.5 (13.6 to 25.4)	0.4 (0.24)	I	18.8 (15.6 to 22.1)	16.4 (12.9 to 20.0)	17.1 (12.4 to 21.9)	(59.0) 2.0-
III, skilled NM	I	27.8	11.8	25.1	-0.2 (0.92)	Ι	19.5	19.4	22.2	0.3 (0.35)
:		(22.0 to 33.6)	(6.5 to 17.1)	(17.8 to 32.4)			(16.6 to 22.5)	(15.6 to 23.2)	(15.5 to 28.8)	
III, skilled M	I	20.5 /17 8 to 72 7/	20.4 /16 / to 2/ //	17.4 (10.7 to 00.1)	-0.3 (0.31)	I	23.5 (17 E to 20 E)	16.9 /10.0 to 22.8/	23.9 (10.1 to 27 7)	0.1 (0.95)
IV nartly skilled	I	(17.8 10 23.2) 23.3	(10.4 10 24.4) 26.6	(12.7 10 22.1) 15 9	-07 (051)	I	(0.62 0) 0.71) 23 1	(10.0 to 23.8) 22 6	(10.1 10 37.77) 19 1	-0.4 (0.23)
		(19.0 to 27.6)	(20.9 to 32.3)	(9.3 to 22.5)			(19.0 to 27.3)	(17.8 to 27.4)	(11.0 to 27.3)	
V, unskilled	Ι	25.4	11.8	34.6	0.9 (0.72)	I	19.9	19.1	20.7	0.1 (0.64)
SII (p value)		(17.3 to 33.6) 13.8 (0.11)	(4.6 to 19.1) 6.4 (0.39)	(26.8 to 42.4) 8.9 (0.43)	-0.5 (0.56)		(13.5 to 26.2) 6.7 (0.14)	(11.8 to 26.3) 6.4 (0.06)	(4.8 to 36.6) 7.2 (0.11)	0.1 (0.56)
*Narativa lower limits have been set to zero	need eve	set to zero	100001	12.22	(222) 222		()	()		
†Aggregated data set.										
‡A different analyser was used for fibrinogen in 2008/2009. M, manual; NM, non-manual; SII, slope index of inequality.	as used anual; SI	for tibrinogen in zuu I, slope index of ine	08/2009. quality.							

contributed to the decline as interviewers, after enrolling one individual, may have been disincentivised to pursue additional householders. Responders to health examination surveys tend to be older, women, of higher socioeconomic class and live healthier lifestyles.⁴⁹ The 2003 SHeS response was modestly skewed towards those in less deprived areas.⁵⁰ A differential response could lead to underestimates for most risk factors in the lower socioeconomic groups, which suggests that true inequalities are even greater than shown here, particularly so for the most recent surveys.

Measurement error will have contributed to bias in these analyses, as will the need to use predicted Omron readings in the first two surveys, the change in laboratories between 1995 and 1998 and the change in fibrinogen analyser between 2003 and 2008/2009. However, the laboratories did use the same methods and reference standards¹⁶ and a high correlation has been demonstrated between the different analysers.⁵¹ These limitations mean caution should be exercised when interpreting prevalence trends but should not greatly distort comparison of socioeconomic gradients. The cross-sectional nature of these surveys does not capture the lifelong burden of these risk markers within individuals, something that might have a considerable effect on subsequent CVD. The increase over time in the proportion of individuals with intermediate educational qualification may in part be a consequence of the subtle changes in how educational achievement was determined across the surveys. These changes would have had no impact on those with no qualifications or those with the highest qualifications. A substantial component of this increase is likely to be due to the rise in the school staying on rates beyond compulsory education seen since the 1970s in Scotland, where intermediate qualifications would be achieved.⁵²

Inconsistency between the socioeconomic measures highlights the benefits of using both education and social class and why they should not be used interchangeably.^{53 54} There were sometimes apparent differences in inequalities depending on the measure used. This may reflect the imperfection of these proxies as measures of deprivation or it may demonstrate the underlying heterogeneity of inequalities. Further research would be valuable. Education reflects the longterm influence of early life circumstance and not only strongly determines an individual's occupation, implying some interdependency with social class, but also provides the knowledge and life skills required to adopt healthier lifestyles and maximise access to health resources.⁵⁵ Alternative indices such as area of deprivation, income and NS-SEC were not consistently available across these surveys. The use of NS-SEC-derived social class in the last three surveys may have led to the misclassification of individuals. This, combined with the shift over time in the composition of social classes and education, may have led to some of the observed alterations in prevalence patterning. However, the SII accounts for the size

of the total population and changes in the distribution of groupings making comparison over time possible. One disadvantage of the SII is that it assumes a linear relationship across the socioeconomic groups, something that may not necessarily be true. The low numbers in the highest and lowest categories may have led to potentially volatile individual estimates, especially in the last two surveys. This was particularly a problem in the 2008/2009 surveys among men with no qualifications in the younger age groups and this may have led to imprecise age-standardised estimates for the lowest educational category and care should be taken in their interpretation.

Small changes in risk factor prevalence at the population level could elicit substantial reductions in CHD mortality.^{56 57} Interventions to achieve such reductions can centre on targeting high-risk individuals,²¹ such as the Keep Well programme⁵⁸ that is aimed at increasing the rate of health improvement among high-risk individuals in the most deprived communities in Scotland. It is too early to assess the impact of this programme on biomarkers for CVD risk but its proposed expansion may increase its effectiveness. Altering the health behaviours of the whole population may have greater impact.^{59 60} In Scotland, there are a number of population-based initiatives aimed at improving health behaviours and consequently the biomarkers for CVD. These include a tobacco control action plan,⁶¹ a national physical strategy,⁶² healthy eating advice⁶³ and an action plan relating to obesity.⁶⁴ If best practice interventions to reduce classic risk factors were successful, most of the absolute socioeconomic differences in CHD mortality could be eliminated.¹² Elimination of relative inequalities may require interventions to be targeted at the socioeconomically disadvantaged (eg, the Keep Well programme) or possibly by improving the circumstances that create social inequality.^{65–66}

The increase in obesity prevalence is probably the driver behind the rise in prevalence of diabetes reported in Scotland over the same period.¹³ In contrast, there has not been a comparable increase in hypertension and cholesterol prevalence, as might be expected. This disassociation between obesity and other risk factors could be due to interventions, such as medication, ameliorating the adverse effects of obesity. It has been shown that obese people in the current century, although having higher risk factor levels than the nonobese, have a lower prevalence of high cholesterol, high blood pressure and smoking than obese individuals 40 years ago.⁶⁷ ⁶⁸ All the above could contribute to explanations as to why overall CHD death rates have continued to fall, despite increasing rates of obesity. If obesity had not increased, there might have been a decline in hypertension prevalence and a greater reduction in hypercholesterolaemia. It is sobering to consider that any gains in CHD mortality by reduction in some risk factors may be offset by additional deaths from obesity and diabetes. These trends could certainly contribute to the observed levelling or slowing of the decline among younger groups. The lack of progress in reducing risk factor socioeconomic inequalities can only ensure such differentials in CVD mortality will remain in the Scottish population. More effective population-wide policies are now urgently required.

Contributors JWH drafted the manuscript, with contributions from all other co-authors. AL and JWH conceived the study design with contributions from the other authors. JWH did all the analyses. JWH is guarantor. All authors had full access to all the data in the study and can take full responsibility for their integrity and the accuracy of their analysis.

Funding The Social and Public Health Sciences Unit is jointly funded by the Medical Research Council and the Chief Scientist Office of the Scottish Government Health Directorate. This research was funded by the Chief Scientist Office as part of the 'Measuring health, variations in health and determinants of health' programme, MC_US_A540_0001. The sponsor had no role in study design or in the collection, analysis and interpretation of data and the writing of the article and the decision to submit it for publication.

Competing interests None.

Ethical approval No ethical approval was required for this study, which was based on publicly available, anonymised Scottish Health Survey data sets.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The Scottish Health Survey data sets used in these analyses are available from the Economic and Social Data Service Data Catalogue http://www.esds.ac.uk/findingData/shlsTitles.asp.

REFERENCES

- Critchley JA, Capewell S, Unal B. Life-years gained from coronary heart disease mortality reduction in Scotland. Prevention or treatment? J Cli Epidemiol 2003;56:583–90.
- O'Flaherty M, Bishop J, Redpath A, *et al.* Coronary heart disease mortality among young adults in Scotland in relation to social inequalities: time trend study. *Br Med J* 2009;339:b2613.
- Wilson A, Siskind V. Coronary heart disease mortality in Australia: is mortality starting to increase among young men? Int J Epidemiol 1995;24:678–84.
- O'Flaherty M, Ford ES, Allender S, *et al.* Coronary heart disease trends in England and Wales from 1984 to 2004: concealed levelling of mortality rates among young adults. *Heart* 2008;94:178–81.
- Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002. J Am Coll Cardiol 2007;50:2128–32.
- Hunink MG, Goldman L, Tosteson AN, *et al.* The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. *JAMA* 1997;277:535–42.
- Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. *Heart* 1999;81:380–6.
- Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. *Circulation* 2004;109:1101–7.
- Mackenbach JP, Bos V, Andersen O, et al. Widening socioeconomic inequalities in mortality in six Western European countries. Int J Epidemiol 2003;32:830-7.
- Beauchamp A, Peeters A, Wolfe R, *et al.* Inequalities in cardiovascular disease mortality: the role of behavioural, physiological and social risk factors. *J Epidemiol Community Health* 2010;64:542–8.
- Strand BH, Tverdal A. Trends in educational inequalities in cardiovascular risk factors: a longitudinal study among 48,000 middle-aged Norwegian men and women. *Eur J Epidemiol* 2006;21:731–9.
- Kivimaki M, Shipley M, Ferrie JE, et al. Best-practice interventions to reduce socioeconomic inequalities of coronary heart disease mortality in UK: a prospective occupational cohort study. Lancet 2008;372:1648–54.
- Hotchkiss JW, Davies CA, Gray L, *et al.* Trends in adult cardiovascular disease risk factors and their socio-economic patterning in the Scottish population 1995-2008: cross-sectional surveys. *BMJ Open* 2011;1:e000176.

- Bromley C, Bradshaw P, Given L, eds. *The Scottish Health Survey* 2008. Edinburgh: The Scottish Government, 2009. http://www. scotland.gov.uk/Publications/2009/09/28102003/0 (accessed 20 Mar 2012).
- Bromley C, Sproston K, Shelton N, eds. *The Scottish Health Survey* 2003. Edinburgh: The Scottish Executive, 2005. http://www.scotland. gov.uk/Publications/2005/12/02160336/03367 (accessed 20 Mar 2012).
- Shaw A, McMunn A, Field J, eds. *The Scottish Health Survey 1998*. Edinburgh: The Stationery Office, 2000. http://www.sehd.scot.nhs.uk/ scottishhealthsurvey/sh8-00.html (accessed 20 Mar 2012).
- Dong W, Erens B, eds. *The Scottish Health Survey 1995*. Edinburgh: The Stationery Office, 1997. http://www.archive.official-documents. co.uk/document/scottish/shealth/shhm.htm (accessed 20 Mar 2012).
- Bromley C, Given L, Ormston R, eds. *The Scottish Health Survey* 2009. Edinburgh: The Scottish Government, 2010. http://www. scotland.gov.uk/Publications/2010/09/23154223/107 (accessed 20 Mar 2012).
- World Health Organisation. *Obesity: Preventing and Managing the Global Epidemic*. 2000. WHO Technical Report Series 894. http://whqlibdoc.who.int/trs/WHO_TRS_894.pdf (accessed 20 Mar 2012).
- Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983–92.
- British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. *Heart* 2005;91(Suppl 5): v1-52.
- Rose D, Pevalin DJ. The National Statistics Socio-Economic Classification: Origins, Development and Use. Appendix 2. Basingstoke, Hampshire, UK: Office for National Statistics, 2005. http://www.ons.gov.uk/ons/guide-method/classifications/archivedstandard-classifications/ns-sec/publication-and-contact-details/ origins-development-use-odu-.pdf (accessed 20 Mar 2012).
- Institute for Social & Economic Research. *Derivations of Social Class,* Web Page. University of Essex, 2012. http://www.iser.essex.ac.uk/ archives/nssec/derivations-of-social-class (accessed 20 Mar 2012).
- 24. Waterhouse J, Muir C, Correa P, et al, eds. Cancer Incidence in Five Continents. Lyon: IARC Scientific Publications, 1976.
- Reigdor E. Measures of health inequalities: part 2. J Epidemiol Community Health 2004;58:900–3.
- Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet* 2011;377:557–67.
- Faeh D, Braun J, Bopp M. Prevalence of obesity in Switzerland 1992–2007: the impact of education, income and occupational class. *Obes Rev* 2011;12:151–66.
- Singh-Manoux A, Gourmelen J, Lajnef M, *et al.* Prevalence of educational inequalities in obesity between 1970 and 2003 in France. *Obes Rev* 2009;10:511–18.
- Prescott E, Godtfredsen N, Osler M, et al. Social gradient in the metabolic syndrome not explained by psychosocial and behavioural factors: evidence from the Copenhagen City Heart Study. Eur J Cardiov Prev R 2007;14:405–12.
- Kavanagh A, Bentley RJ, Turrell G, *et al.* Socioeconomic position, gender, health behaviours and biomarkers of cardiovascular disease and diabetes. *Soc Sci Med* 2010;71:1150–60.
- Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. *Lancet* 2011;377:568–77.
- Kanjilal Ś, Gregg EW, Cheng YJ, et al. Socioeconomic status and trends in disparities in 4 major risk factors for cardiovascular disease among US adults, 1971-2002. Arch Intern Med 2006;166:2348–55.
- Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010;39:504–18.
- Primatesta P, Poulter NR. Improvement in hypertension management in England: results from the Health Survey for England 2003. J Hypertens 2006;24:1187–92.
- Strandhagen E, Berg C, Lissner L, et al. Selection bias in a population survey with registry linkage: potential effect on socioeconomic gradient in cardiovascular risk. Eur J Epidemiol 2010;25:163–72.
- Shewry MC, Smith WS, Woodward M, *et al.* Variation in coronary risk factors by social status: results from the Scottish heart health study. *Br J Gen Pract* 1992;42:406–10.
- 37. Anderson CA, Appel LJ, Okuda N, et al. Dietary Sources of Sodium in China, Japan, the United Kingdom, and the United States, women

and men aged 40 to 59 years: the INTERMAP study. J Am Diet Assoc 2010;110:736-45.

- Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. *Lancet* 2011;377:578–86.
- McFadden E, Luben R, Wareham N, et al. Occupational social class, risk factors and cardiovascular disease incidence in men and women: a prospective study in the European Prospective Investigation of Cancer and Nutrition in Norfolk (EPIC-Norfolk) cohort. Eur J Epidemiol 2008;23:449–58.
- Rehkopf DH, Kreiger N, Coull B, *et al.* Biologic risk markers for coronary heart disease. Nonlinear associations with income. *Epidemiology* 2010;21:38–46.
- Woodward M, Shewry MC, Smith WCS, et al. Social status and coronary heart disease: results from the Scottish Heart Health Study. Prev Med 1992;21:136–48.
- Atherton K, Power C. Health inequalities with the National Statistics-Socioeconomic classification: disease risk factors and health in the 1958 British birth cohort. *Eur J Public Health* 2007;17:486–91.
- Keavney B, Danesh J, Parish S, *et al.* Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'. *Int J Epidemiol* 2006;35:935–43.
- 44. Wensley F, Gao P, Burgess S, *et al*; C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. *BMJ* 2011;342:d548.
- Fortmann SP, Ford ES, Criqui MH, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice report from the population science discussion group. *Circulation* 2004;110:e554–9.
- 46. Welsh P, Woodward M, Rumley A, *et al.* Associations of plasma proinflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. *Br J Haematol* 2008;141:852–61.
- Ramsay S, Lowe GD, Whincup PH, et al. Relationships of inflammatory and haemostatic markers with social class: results from a population-based study of older men. Atherosclerosis 2008;197:654–61.
- Lawlor DA, Davey Smith G, Rumley A, et al. Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors. *Thromb Haemost* 2005;93:955–63.
- Tolonen H, Dobson A, Kulathinal S. Effect on trend estimates of the difference between survey respondents and non-respondents: results from 27 populations in the WHO MONICA project. *Eur J Epidemiol* 2005;20:887–98.
- Lawder R, Harding O, Stockton D, *et al.* Is the Scottish population living dangerously? Prevalence of multiple risk factors: the Scottish Health Survey 2003. *BMC Public Health* 2010;10:330.
- Craig R, Mindell J, eds. *Health Survey for England 2006. Volume 3:* Methodology and Documentation. Leeds: The Information Centre, 2008. http://www.ic.nhs.uk/webfiles/publications/HSE06/ HSE06_VOL3.pdf (accessed 20 Mar 2012).

- Raffe D. Upper-secondary education. In: Clark MM, Munn P, eds. Education in Scotland Policy and Practice from Pre-school to Secondary. London: Routledge, 1997:67–80.
- Geyer S, Hemstrom O, Peter R, et al. Education, income and occupational class cannot be used interchangeably in social epidemiology. Empirical evidence against a common practice. J Epidemiol Community Health 2006;60:804–10.
- Davey Smith G, Hart CL, Watt G, *et al.* Individual social class, areabased deprivation, cardiovascular disease risk factors, and mortality: the Renfrew and Paisley study. *J Epidemiol Community Health* 1998;52:399–405.
- 55. Galobardes B, Shaw M, Lawlor DA, *et al.* Indicators of socioeconomic position (part 1). *J Epidemiol Community Health* 2006;60:7–12.
- Unal B, Critchley JA, Capewell S. Small changes in United Kingdom cardiovascular risk factors could halve coronary heart disease mortality. *J Clin Epidemiol* 2005;58:733–40.
- Critchley JA, Capewell S. Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels. J Epidemiol Community Health 2003;57:243–7.
- 58. Health Scotland. *Keep Well Website*. 2012. http://www. healthscotland.com/anticipatory-care/programmes/keepwell.aspx (accessed 20 Mar 2012).
- 59. National Institute for Health and Clinical Excellence. *Prevention of Cardiovascular Disease at Population Level*. London: NICE, 2010. http://guidance.nice.org.uk/PH25 (accessed 20 Mar 2012).
- Emberson JR, Whincup PH, Morris R, *et al.* Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. *Eur Heart J* 2004;25:484–91.
- Scottish Executive. A Breath of Fresh Air for Scotland. Improving Scotland's Health: The Challenge Tobacco Control Action Plan. Edinburgh: Scottish Executive, 2004. http://www.scotland.gov.uk/ Resource/Doc/26487/0013536.pdf (accessed 20 Mar 2012).
- Physical Activity Task Force. Lets Make Scotland More Active: A Strategy for Physical Activity. Edinburgh: Scottish Executive, 2003. http://www.scotland.gov.uk/Resource/Doc/26487/0013536.pdf (accessed 20 Mar 2012).
- NHS choices website. 5 A Day. 2011. http://www.nhs.uk/livewell/ 5aday/Pages/5ADAYhome.aspx (accessed 20 Mar 2012).
- The Scottish Government. Preventing Overweight and Obesity in Scotland a Route Map Towards Healthy Weight. Edinburgh: Scottish Government, 2010. http://www.scotland.gov.uk/Resource/Doc/ 302783/0094795.pdf (accessed 20 Mar 2012).
- Commission on Social Determinants of Health. Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health. Final Report. Geneva: WHO, 2008. http:// whqlibdoc.who.int/publications/2008/9789241563703_eng.pdf (accessed 20 Mar 2012).
- Frohlich KL, Potvin L. The inequality paradox: the approach and vulnerable populations. *Am J Public Health* 2008;98:216–21.
- 67. Gregg EW, Cheng YJ, Cadwell BL, *et al.* Secular trends in cardiovascular disease risk factors according to body mass index in US adults. *JAMA* 2005;293:1868–74.
- Rosengren A, Eriksson M, Hansson PO, et al. Obesity and trends in cardiovascular risk factors over 40 years in Swedish men aged 50. J Intern Med 2009;266:268–76.